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Abstract 
Effective cholesterol homeostasis is essential in maintaining cellular function, and this is achieved 
by a network of lipid-responsive nuclear transcription factors, and enzymes, receptors and 
transporters subject to post-transcriptional and post-translational regulation, while loss of these 
elegant, tightly regulated homeostatic responses is integral to disease pathologies.   Recent data 
suggest that sterol-binding sensors, exchangers and transporters contribute to regulation of cellular 
cholesterol homeostasis and that genetic overexpression or deletion, or mutations, in a number of 
these proteins are linked with diseases, including atherosclerosis, dyslipidaemia, diabetes, 
congenital lipoid adrenal hyperplasia, cancer, autosomal dominant hearing loss and male infertility.  
This review focuses on current evidence exploring the function of members of the ‘START’ 
(steroidogenic acute regulatory protein-related lipid transfer) and ‘ORP’ (oxysterol-binding protein-
related proteins) families of sterol-binding proteins in sterol homeostasis in eukaryotic cells, and the 
evidence that they represent valid therapeutic targets to alleviate human disease. [144 words]   
Short title Intracellular cholesterol transporters in health and disease 
Keywords Cholesterol homeostasis; non-vesicular lipid trafficking; sterol-responsive 
transcription factors; Steroidogenic acute regulatory protein (StAR)-related lipid 
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ABC   ATP binding cassette transporter 
ACAT-1/2  Acyl CoA: Cholesterol Acyl Transferase (1/2)  
AMPK  5’-AMP activated protein kinase 
Apo  Apolipoprotein 
ApoER2  Apolipoprotein E receptor-2 
ATF6  Activating transcription factor 6 
CE  Cholesteryl esters 
CYP7A1  Cytochrome P540 family 7 subfamily A member 1 
CYP27A1                              Cytochrome P450 family 27 subfamily A member 1 
DGAT  Diacylglycerol acyltransferase 
ERBB2  ERBB2 receptor tyrosine kinase 2 (CD340) 
ERC  Endocytic recycling compartment 
ERSE  ER stress response element 
FFAT  Two phenylalanines in an acid tract (domain) 
GAP  GTP activating protein 
GATA  ‘GATA’ binding transcription factor 
HDAC5  Histone deacetylase 5 
HDL  High density lipoprotein 
HMCGR  3-Hydroxy methyl glutaryl CoA reductase 
HOPS HOPS complex: 6 subunits of VPS (vacuole protein sorting) proteins [VPS11, 
VPS16, VPS18, VPS33, VPS39 and VPS41] 
IDOL  Inducible Degrader of the Low Density Lipoprotein Receptor 
IMM  Inner mitochondrial membrane 
INSIG-1/2  Insulin Induced Gene (1/2) 
Lam  Lipid transfer protein anchored at membrane contact sites 
LCAT  Lecithin Cholesterol Acyl Transferase 
LDL  Low density lipoprotein 
LDLR  Low density lipoprotein receptor 
LRP  LDL receptor related protein 
LXR  Liver X receptor 
MENTAL  MLN64 N-terminal domain 
MENTHO  STARD3 N-terminal like protein 
MLN64  STARD3 
NASH  Non-alcoholic steatohepatitis 
NLRP4  NLR family, pyrin domain-containing 4 
NPC-1/2  Niemann Pick disease type C1/2 
Nup62  Nucleoporin 62kDa 
OMM  Outer mitochondrial membrane 
ORD  Oxysterol binding protein-related ligand-binding domain 
ORP  Oxysterol binding protein related protein 
OSBP  Oxysterol binding protein 
PCSK9  Proprotein convertase subtilisin kexin type 9 
PH  Pleckstrin homology (domain) 
PI-3P  Phosphatidylinositol 3-phosphate 
PI-4P  Phosphatidylinositol 4-phosphate 
PM  Plasma membrane 
PPAR  Peroxisome proliferator activated receptor 
RAB7  Ras related protein Rab7a 
RCT  Reverse cholesterol transport 
RILP  Rab-interacting lysosomal protein 
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RXR  Retinoid X receptor 
SCAP Sterol regulatory element binding protein (SREBP) cleavage activating 
protein 
SCP-2 Sterol Carrier Protein-2 
SIRT1 Sirtuin 1 
SNARE Soluble N-ethylmaleimide-sensitive factor activating protein receptor 
SQS/FDFT Squalene synthase/farnesyl-diphosphate farnesyltransferase 1 
SPAG5 Homo sapiens sperm associated antigen 5 
SRE  Sterol regulatory element 
SREBP  Sterol regulatory element binding protein 
StAR  Steroidogenic acute regulatory protein 
STARD  StAR-related domain 
START  StAR-related lipid transfer protein 
SUMO-1  Small ubiquitin-like modifier 1 
VAMP  Vesicle-associated membrane proteins 
VAP  VAMP associated proteins 
VLDLR  VLDL receptor 





























Cholesterol is the precursor for bile acids, steroid hormones and vitamin D, which regulate the 
absorption of dietary lipid, glucose metabolism, kidney and reproductive function and bone 
homeostasis, while imbalanced cholesterol metabolism results in embryonic and adult disease 
(recently reviewed by Cortes et al (2014) [1].   Aberrant serum and tissue cholesterol levels are 
caused by rare genetic disorders, and form part of the pathogenesis of more prevalent sporadic and 
complex disorders, including coronary heart disease, stroke, diabetes mellitus and Alzheimer’s 
disease.  Effective cellular cholesterol homeostasis is achieved by lipid-responsive transcription 
factors, and an array of post-transcriptional and post-translational mechanisms, controlling the 
biosynthesis, efflux (egress), oxidative metabolism, storage and uptake (ingress) of this sterol.    
Biosynthesis of cholesterol occurs in the endoplasmic reticulum, from whence this sterol is directed 
to the Golgi apparatus and plasma membrane (PM), or esterified via Acyl CoA Cholesterol: Acyl 
Transferase (ACAT-1/2) and stored as cytosolic lipid droplets of cholesteryl ester (CE), recently 
reviewed by Rogers et al (2015) [2] and Khor et al (2013) [3]. Transcriptional regulation of cholesterol 
synthesis and uptake involves Sterol Regulatory Element Binding Proteins (SREBPs)[4], a class of 
transcription factors belonging to the basic helix-loop-helix leucine zipper (bHLH-Zip) family. Two 
genes, SREBF-1 and -2, code for three distinct SREBP isoforms: -1a, -1c and -2. SREBP-1a is 
constitutively expressed in the cell as a ‘low-specificity’ regulator, targeting all genes that contain 
sterol response elements (SRE)[5]. By contrast, SREBP-1c and SREBP-2 are inducible and promote 
the expression of genes encoding proteins involved in fatty-acid and cholesterol metabolism, 
respectively [5] (Figure 1A). 
The gene expression of Srebf-2 is regulated in a ‘feed-forward’ manner, with SREBP-2 binding to the 
SREs present within its own promoter [6], and SREBPs are subjected to multiple levels of post-
translational regulation [7-12].  Following translation, and in the presence of adequately high levels 
of intracellular sterols, SREBPs are inactive and retained within the endoplasmic reticulum by 
SREBP cleavage activating protein (SCAP), a chaperone protein characterised by a five 
transmembrane sterol-sensing domain, which interacts with the endoplasmic reticulum anchor, 
Insulin Induced Gene (INSIG-1/2).    Conversely, when sterol levels within the cell fall, binding of 
INSIG to SCAP is disrupted, leading to the inclusion of the SCAP-SREBP complex in COPII-vesicles, 
and subsequent transfer to the Golgi apparatus. Golgi-resident site-1 and site-2 proteases (SP-1 and 
SP-2) cleave and release the amino terminal of SREBP [12, 13], the transcriptionally active portion 
that travels to the nucleus and targets sterol-responsive genes; this fragment is subsequently 
rapidly degraded to terminate this signalling pathway.  Further, the stability of SREBP proteins is 
modulated by acetylation, increased by p300 [7], and reduced by SIRT1, which favours the rapid 
degradation of SREBPs [8].  Deacetylation of SREBPs facilitates the action of ubiquitin ligases, thus 
resulting in proteosomal degradation [9, 10], while SUMO-1 mediates degradation of SREBPs 
independently of the 26S proteasome [11]. 
Collectively, SREBP-2 regulates most the enzymes of the mevalonate pathway, which produces 
cholesterol as well as essential isoprenoids used for the synthesis of hormones and signalling 
molecules [14]. The rate limiting step in this pathway is mediated by 3-Hydroxy Methyl Glutaryl CoA 
Reductase (HMGCR) which is transcriptionally regulated by SREBP-2, but also by negative feedback 
[recently reviewed by Ness, 2015 [15]).  The HMGCR protein undergoes ubiquitination upon 
accumulation of sterol intermediates (mainly lanosterol and 24,25-dehydrolanosterol) and 
cholesterol metabolites such as oxysterols[16-18], ultimately leading to its proteasomal 
degradation; squalene synthase (SQS) is also negatively regulated by accumulation of cholesterol in 
a similar manner.  The activity of HMGCR is also controlled by 5' AMP-activated protein kinase 
(AMPK), that senses the energy status of the cell, which suppresses sterol synthesis following 
increases in the AMP/ATP ratio [19]. 
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The transcription of SREBPs also stimulates the expression of intronic micro-RNAs -33a and -33b, 
which lie within the genomic sequence of Srebf-2 and Srebf-1, respectively[20], which suppress the 
translation of ATP binding cassette transporter A1 (ABCA1) (below), reducing the efflux (egress) of 
cholesterol from the cell.  This response ensures that newly synthesized cholesterol remains within 
the cell, rather than effluxed to extracellular acceptors. Indeed, a number of microRNA sequences 
are involved in regulation of the cholesterol homeostasis, either directly, by repressing the 
expression of genes and proteins involved in cholesterol synthesis and transport, or indirectly, by 
modulating the lipid metabolism and energy status of the cell [20, 21] and recently reviewed by 
Jeon and Osborne, 2016 [22] and DiMarco and Fernandez (2015) [23]. 
Cellular cholesterol can also be derived from the extracellular medium or the bloodstream by 
endocytosis of lipoproteins, such as low density lipoprotein (LDL) and other apoE-containing 
lipoproteins, via an array of receptors, including the LDL receptor (LDLR), LDL receptor related 
protein (LRP1 (CD91; -2-macroglobulin receptor), LRP2 (GP300; megalin), LRP5 (LRP7), LRP6, 
LRP8 (apoE receptor 2) and the VLDL receptor (VLDLR) [24, 25].   Receptor-lipoprotein complexes 
are internalised via clathrin-coated vesicles, delivering LDL and other lipoproteins to the endocytic 
pathway, resulting in degradation of these complexes by hydrolytic enzymes in acidic 
(endo)lysosomal vesicles.  Cholesterol leaves the endocytic pathway by the action of proteins that 
mediate its stepwise removal, as cargo associated with budding vesicles, or by intramembrane 
exchange with acceptor organelles via membrane contact sites.  The first steps in protein-mediated 
egress of cholesterol are mediated by Niemann-Pick disease type-C1 and type-C2 proteins (NPC-
1/2)[26,27], localized in the membrane and the lumen of late endosomes, respectively. NPC1 is 
thought to deliver cholesterol molecules to cytoplasmic transporters, which in turn supply this 
sterol to mitochondria and endoplasmic reticulum [28-36].  Small GTPases belonging to the Rab 
family regulate vesicle transport, by facilitating interactions with the actin filaments of the 
cytoskeleton [37-40], directing lipoprotein-derived cholesterol to intracellular organelles as well as 
recycling back to the plasma membrane [28].  
The distribution of lipoprotein-derived cholesterol to organelles triggers the activation of counter-
regulatory pathways. Delivery of cholesterol to the endoplasmic reticulum sequesters SREBPs at 
this site, by interaction with SCAP and INSIG, curtailing the generation of active SREBPs, while 
increased trafficking of cholesterol to mitochondria sterol 27-hydroxylase facilitates production of 
oxysterols, which act as ligands for nuclear transcription factors, Liver X Receptors (LXRs) [reviewed 
in 41-43].  These nuclear receptors heterodimerize with Retinoid X Receptors (RXRs), operating in 
functional opposition to SREBPs, reducing the expression levels of Ldlr and the enzymes in the 
mevalonate pathway (above)[14, 44]. Liver X Receptors also promote the protein degradation of 
LDLR, by increasing the expression of Proprotein convertase subtilisin/kexin type 9(PCSK9)[45] and 
the action of E3 ubiquitin ligase, inducible degrader of the low-density lipoprotein receptor 
(IDOL)[46].  
Activation of LXRs also stimulates the reverse cholesterol transport (RCT) pathway [41-43], which 
removes excess cholesterol from cells and tissues, returning this sterol via high density lipoproteins 
(HDL) to the liver, reviewed by Rye and Barter (2014) [47] and Wang and Smith (2014) [48].  
Oxysterol ligation of LXR/RXR heterodimers increases the transcription of ABCA1 and 
ABCG1/ABCG4, which efflux cholesterol to extracellular acceptors, apolipoprotein A-I (apoA-I) and 
HDL, respectively. The transcription of apolipoprotein E (ApoE) is also increased by ligation of LXRs, 
which can act as an extracellular acceptor of cholesterol, and enhance the efficiency of the RCT by 
stimulating the action of lecithin-cholesterol acyltransferase (LCAT), an HDL-bound enzyme that 
promotes the extracellular conversion of cholesterol to CE in the circulation[49], creating a 
concentration gradient favouring the continued removal of free cholesterol from tissues in the 
periphery.  Removal of cholesterol from the body is achieved by hepatic conversion to bile acids: 
activated LXR/RXR heterodimers stimulate the expression of rate-limiting enzyme CYP7A1, 
resident in the ER [50],of mitochondrial Cyp27A1 responsible for the ‘acidic’ or alternative pathway, 
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and the half-transporters ABCG5 and ABCG8 which efflux cholesterol into bile [51] and recently 
reviewed by Li et al., 2013 [52].  Mutations in ABCG5/8 cause -sitosterolaemia: the accumulation of 
cholesterol and plant sterols which can eventually lead to premature coronary disease [51, 52].   
The loss of these elegant, tightly regulated homeostatic responses plays an integral role in a 
number of disease pathologies, including metabolic diseases, tumourigenesis and disorders of the 
central nervous system.  Within the arterial intima, for example, oxidation or enzymatic 
modification of LDL leads to recognition of modified LDL by scavenger receptors, including 
scavenger receptor (SR-)AI/AII, Cluster of Differentiation (CD)36, CD68 and lectin-like oxidized low-
density lipoprotein (LDL) receptor-1 (LOX-1), leading to CE accumulation in LD and activation of 
inflammasomes [53-56].  Cholesterol and CE-laden macrophage ‘foam’ cells characterise early ‘fatty 
streak’ atheroma, while their apoptosis or necrosis contribute to the extracellular lipid core and 
cholesterol crystals found within more advanced lesions [53-56].  
Cholesterol crystals are also found within hepatocyte lipid droplets in non-alcoholic steatohepatitis 
(NASH).  These dead cells are removed by Kupffer cells, loading these cells with lipid and triggering 
the inflammatory responses linked with progression of steatosis to NASH [57-59].  Osteoporosis 
and deficient bone repair has been linked to elevated serum cholesterol [60-62], while cholesterol-
laden histiocytes characterise the rare multi-system granulomatosis noted in Erdheim-Chester 
disease [63].   Lipid accumulation within alveolar macrophages is associated with pulmonary 
inflammation [64], while patients with pulmonary alveolar proteinosis display alveolar ‘foam’ cells, 
due to functional loss of granulocyte macrophage colony stimulating factor [65].   
The supply of excess cholesterol and the provision of intermediates from the mevalonate pathway 
also appear to be central to the high rate of proliferation of some cancer cells, reviewed in [66] and 
more recently by Kuzu et al., 2016 [67].  For example, cholesterol biosynthesis via HMGCR is 
enhanced in gastric cancer tissues:  overexpression of this enzyme promoted growth and migration 
of gastric cancer cells, while knockout of HMGCR achieved the reverse [68].  Dietary cholesterol has 
also been linked with promotion of colorectal cancer, via activation of the NLR family, pyrin 
domain-containing 4 (NLRP4) inflammasome [69], and statin inhibitors of HMGCR have been 
proposed as anti-tumourigenic agents [reviewed in 70].    By contrast, activation of LXR blocks the 
growth of human colorectal cells and of xenograft tumours in mice; protection is also provided 
against intestinal tumour formation after treatment with chemical carcinogens [71].   Further, while 
hypermethylation of ABCA1 is associated with accelerated cell growth and poor prognosis in 
ovarian cancer patients [72], induction of ABCA1 expression and cholesterol efflux follows 
treatment with DNA topoisomerase II inhibitors, chemotherapeutics used in the treatment of 
various cancers [73].  
Finally, loss of effective cholesterol homeostasis is a feature of ageing and of diseases of the central 
nervous system (CNS) [74-78] and a recent review by Courtney and Landreth (2016) [79].   ApoE is 
lipidated by astrocytes and glia within the CNS, generating lipoproteins that provide cholesterol to 
support the function of neuronal cells, and aid the transport and clearance of amyloid  peptide 
[reviewed in 74], and dysregulated cholesterol metabolism is an established feature of Alzheimer’s 
disease, Parkinson’s disease and traumatic central nervous system injury [74-79].  The 
neurodegenerative disorder, Huntington’s disease, caused by the mutant huntingtin protein (mHtt) 
[77] is associated with loss of nuclear SREBPs and defective activation of LXR, resulting in lower 
cholesterol biosynthesis and reduced apoE-dependent transport of cholesterol from astrocytes to 
neurons [77].  Genetic defects in endosomal Niemann-Pick type C1 (NPC1) protein cause 
neurological dysfunction [78], and loss-of-function mutations in ABCA1, which cause low or absent 
levels of HDL, are thought to contribute to peripheral neuropathies in patients with Tangier disease 
[80]. 
INTRACELLULAR TRANSPORT OF CHOLESTEROL 
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Inter-organelle lipid transport occurs via the movement of transport vesicles, by transport by lipid 
binding/transfer proteins, and by diffusion across closely apposed membrane leaflets, although the 
major portion of inter-organelle transport seems to occur via non-vesicular mechanisms [28-32; 
81,82].  In particular, it seems that transfer of lipid molecules over the narrow gap between lipid 
bilayers at membrane contact sites is a specific and efficient means of achieving lipid transport 
(Figure 1B).   
A number of proteins, including Sterol Carrier Protein-2 (SCP-2) and the families of steroidogenic 
acute regulatory protein (StAR)-related domain lipid transfer (START) proteins, and oxysterol 
binding protein-related proteins (ORPs), are thought to contribute to the non-vesicular transport of 
cholesterol within the aqueous environment of the cytosol, and between organelles and the plasma 
membrane, sustaining the sterol gradient that exists between the endoplasmic reticulum and the 
plasma membrane [81-83].   Until around a decade or so ago, the role of most of these proteins 
remained relatively uncharacterised.  However, it is becoming increasingly clear that sterol-binding, 
‘sensing’ and trafficking proteins influence the expression and activity of sterol-responsive 
transcription factors, regulating the expression of genes encoding proteins which synthesize, 
metabolise and efflux cholesterol, and direct the trafficking of cholesterol between the plasma 
membrane, mitochondria, Golgi and endosomal and lysosomal compartments, defining the fate of 
this lipid [81-83] (Figure 1B).  This review will focus on recent data exploring the function of the 
START and ORP proteins in cholesterol homeostasis in eukaryotic cells, and the evidence 
suggesting that they represent valid therapeutic targets to alleviate disease pathologies. 
Human START proteins are a family of fifteen members, sharing a conserved 210-residue 
hydrophobic binding pocket, further classified into six sub-groups according to the degree of 
sequence homology of this StAR-related lipid transfer domain [84].  The structure of the START 
domain has been resolved for eight START proteins (STARD1 to D5, -D11, D13 and D14), showing 
that a single lipid molecule is accommodated in an hydrophobic cleft which arises from the spatial 
organization of 9 anti-parallel β-sheets arranged to form a hollow concave profile, closed at its 
extremities by two α-helices, while a third α-helix operates as ‘lid’, allowing the ingress and egress 
of the lipid molecule [85-89]. Additional domains are found in seven STARTs, specifically involved in 
determining their subcellular localization as well as conferring additional physiological functions 
[84].    
The STARD1 subgroup is composed of StAR/STARD1 and STARD3.  STARD1, the prototypic 
member of this family, possesses a mitochondrial targeting sequence and supplies cholesterol 
substrate for conversion to pregnenolone [90-92], while STARD3 localizes to the late endosomes, 
where it participates in the extraction of cholesterol as well as regulating their spatial organization 
[36, 39, 93].   The other subgroups of cholesterol-binding proteins (STARD4) contains  STARD4, 
STARD5 and STARD6, which are devoid of targeting sequences and  may operate as cytosolic 
cholesterol exchangers between membranes, their directionality being regulated by the 
intracellular gradient of sterols [35, 94, 95]. The STARD2 subgroup (STARD2, STARD10, 
STARD11/CERT) binds phospholipids and ceramides [96-99] while STARD9 possesses an N-terminal 
kinesin motor capable of interacting with and moving along microtubules [100, 101].  The other 
subgroups include Rho-GAP STARTs (STARD12, STARD13), which possess a Rho-GTP activating 
protein (GAP) domain involved in regulating the activity of Rho-GTPases and the cytoskeleton 
[102], and the thioesterase STARTs, STARD14 and STARD15, which hydrolyse long chain fatty acyl 
CoA and acetyl CoA, respectively [102-105]. 
By contrast, the family of human oxysterol binding protein (OSBP)-Related Proteins (ORPs) 
comprehends twelve distinct members (ORP1-12) divided into six subfamilies, with some ORPs 
occurring as short (S) and long (L) variants [reviewed in 106].  OSBP, the first ORP to be identified 
and characterized, was originally described as a 25-hydroxycholesterol transporter, and later shown 
to be able to bind other oxysterols, as well as cholesterol and ergosterol [106].  Ligands, which can 
include glycerophospholipids, are accommodated within an OSBP-related ligand-binding domain 
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(ORD) that is arranged as a hydrophobic β-barrel where the sterol is accommodated with the 3β-
hydroxyl group oriented inwards and enclosed on the distal side by an N-terminal lid [106]. Most 
ORPs are found in association with the membranes of adjacent organelles and are constituents of 
membrane contact sites. The ORPs possess a pleckstrin homology (PH) domain, which can interact 
with phosphoinositide containing membranes, and a “two phenylalanines in an acid tract” (FFAT) 
domain, which binds to proteins (VAPs) associated with vesicle-associated membrane proteins 
(VAMPs)[106, 107].   Further, ORPs can interact with membrane-associated regulatory proteins, 
including small GTPases Arf1 and Rab7 [106].  The concept of ‘dual targeting’ describes the ability of 
ORPs to target two distinct membranes via these distinct binding sites, and in recent years it has 
become clear that this property may be critical in facilitating bi-directional lipid transfer at protein 
complexes found at membrane contact sites between differing organelles.  Indeed, ORPs are 
thought to utilise the energy stored within the intracellular gradient of phosphatidylinositol 4-
phosphate (PI-4P) to power the transport of sterols or other lipids against their concentration 
gradient at inter-organelle bridges [106].  
 
Sterol-binding proteins: mitochondria 
Steroidogenic acute regulatory protein (StAR; STARD1) plays a well-established, obligate role in the 
acute steroidogenic response regulated by StAR-dependent delivery of cholesterol from the outer 
mitochondrial membrane (OMM) to the inner mitochondrial membrane (IMM), facilitating 
generation of pregnenolone from cholesterol by cytochrome P450scc (CYP11A1) [90-92] and 
reviewed extensively in 108-112].   StAR is synthesized as a 37kDa protein, with a mitochondrial 
leader sequence that is subsequently cleaved following mitochondrial entry to yield a 30kDa intra-
mitochondrial protein.  Overexpression of StAR increases steroidogenesis, primarily via its activity 
at the OMM, where a physical interaction between the C-terminal helical ‘lid’ and the membrane is 
required to allow release of cholesterol to the membrane [108].  Notably, loss-of-function 
mutations in StAR cause the autosomal recessive disorder, congenital lipoid adrenal hyperplasia, 
characterised by minimal production of all steroids and grossly enlarged adrenals filled with 
cholesterol and CE [110, 113], a phenotype replicated in StAR knockout mice [114].   
At least 48 different mutations in StAR have been identified in various ethic groups, that typically 
cause severe adrenal failure in early infancy, although delayed onset of adrenal insufficiency has 
also been reported in some individuals [115].   Genetic clusters consistently occur in Japanese and 
Korean populations (p.Q258X), Palestinian Arab (p.R182L), eastern Saudi Arabian (p.R182H) and 
Swiss (p.L260P) populations [115].   Affected infants have low, but measurable, levels of steroid 
hormones, but unless hormone replacement is initiated soon after birth, the condition proves lethal 
during the first year of life due to loss of glucocorticoid and mineralocorticoid production and salt 
loss [116, 117].  Loss of StAR causes defective foetal testicular biosynthesis: affected 46,XY males 
are born with feminised genitalia reflecting the loss of androgen synthesis between 6 and 12 weeks 
of gestation [115].  Female 46,XX subjects with congenital lipoid hyperplasia are also affected at 
puberty, when ovarian steroidogenesis is programmed to initiate; loss of steroidogenesis and 
accumulation of cholesterol and cholesteryl esters leads to cellular damage, anovulatory cycles, 
polycystic ovaries and and ovarian failure [115, 117].   
More recently, it has become evident that StAR is expressed and functional in non-steroidogenic 
cells, albeit at substantially lower levels than in adrenal or gonadal tissues [119].  For example, the 
expression of StAR is noted in endothelial cells, monocytes, macrophages and human aorta, and 
subject to regulation by cytokines, LXR, peroxisome proliferator activated receptor  (PPAR and 
RXR agonists, and by modified LDL [120-122].  Notably, overexpression of StAR promotes 
cholesterol efflux to apoA-I and/or HDL, by enhancing the formation of oxysterols by mitochondrial 
cytochrome P450 enzyme, CYP27A1, activation of LXR, and induction of ABCA1/ABCG1 mRNA 
and protein [34,123-125 ].  However, under pathological conditions, macrophage StAR can transfer 
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damaging cholesterol hydroperoxides to mitochondria, causing lipid peroxidation and loss of 
mitochondrial membrane polarisation, and reduced expression of ABCA1 [125].   The systemic 
effects of StAR are evident in apoE-/- mice fed a high fat/cholesterol diet, which display reduced 
levels of hepatic and hepatic and aortic lipids and decreased atheroma following tail vein 
administration of an adenoviral vector expressing StAR [126].   Furthermore, in primary hepatocytes 
overexpression of StAR enhances bile acid synthesis via CYP27A1 [127], while in rat hepatoma cells 
StAR overexpression increased utilisation of exogenous (pre-formed) fatty acids for the synthesis 
and secretion of triacylglycerol; these changes were associated with increased gene expression of 
diacylglycerol acyl transferase-1 (Dgat1) and Dgat2 [128].   
Until very recently, no ORPs had been observed at endoplasmic reticulum-mitochondrial contact 
sites, and no function ascribed for ORPs in endoplasmic reticulum-mitochondrial transport, 
biogenesis, division or fusion.   However, Galmes et al (2016) have now described the localisation of 
ORP5 and ORP8 at endoplasmic reticulum-mitochondria contact sites, transporting 
phosphatidylserine to the mitochondria for subsequent synthesis of phosphatidylethanolamine 
[129].  This localisation requires a functional ORD, and involves interaction with the OMM protein, 
PTPIP51.  Notably, depletion of ORP5 and ORP8 (discussed further below) led to defects in 
mitochondrial morphology and mitochondrial respiration [129].   
Sterol-binding proteins: cytosolic 
The STARD4 subgroup of START proteins, STARD4, STARD5 and STARD6, consist predominantly 
of a 205-233 amino acid START domain [31, 35, 94, 95].  StarD4 was discovered as a gene whose 
expression decreased >2-fold in the livers of mice fed a high cholesterol diet [130], and together 
with StarD5 and StarD6 constitute a subfamily sharing approximately 30% amino acid identity with 
one another [83, 84; 116]. Recently, it has become clear that the conserved residues of STARD1 
(above), STARD3 (below), STARD4, STARD5 and STARD6 STARD create the global protein fold, 
those lining the ligand binding site diverge, conferring specificity in ligand binding [94, 95, 131].    
Levels of StarD4 mRNA and protein are repressed by the accumulation of cholesterol in fibroblasts 
and liver tissues, StarD4 is an established target of SREBP-2, and genetic obesity in rodents is 
associated with reduced hepatic expression of StarD4 [31, 35, 94, 95, 131-133].   Endoplasmic 
reticulum stress has also been reported to induce STARD4 via Activating transcription factor 6 
(ATF6) and an endoplasmic reticulum stress response (ERSE)-like element within its promoter [95].   
The interaction of STARD4 with membranes, and its sterol binding and release, reveals a model 
requiring dynamic movement of the Omega-1 loop, covering the sterol binding pocket, and 
insertion of the C-terminal -helix into the membrane bilayer [131].   
Overexpression of StarD4 increases sterol delivery to the endocytic recycling compartment and the 
endoplasmic reticulum, and enhances cholesterol esterification via ACAT in macrophages, 
fibroblasts and hepatocytes; silencing of STARD4 diminishes cholesterol-mediated regulation of 
SREBP-2 activation, while its overexpression achieves the reverse [35, 131-139].    In rodent 
hepatoma cells, overexpression of StarD4 increased the lipidation of exogenous apoA-I, without 
impacting on triacylglycerol synthesis or secretion [133] while knockdown of STARD4 led to the 
accumulation of cholesterol at the plasma membrane [138].  Overexpression of STARD4 can also 
increase the formation of bile acids, so that cholesterol catabolism is enhanced [135].  In 
keratinocytes (HaCaT), transient overexpression of STARD4 decreased the biosynthesis of 
cholesterol and CE, and triggers increased expression of SREBF2, ABCG4 and loricrin, but represses 
expression of ABCA1, suggesting modulation of both keratinocyte cholesterol metabolism and 
differentiation status [138].  Bazuine et al (2009) have suggested that both StarD4 and OSBP are 
targets of the p53 tumour suppressor protein, modifying cellular responses to stress caused by 
reactive oxygen species and lipotoxicity [139].  However, like StAR, StarD4 can facilitate the 
translocation of 7-hydroperoxycholesterol to isolated mitochondria resulting in greater vulnerability 
to peroxidation by free radicals and mitochondrial membrane depolarisation [140].  Global 
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knockout of StarD4 leads to modest weight loss, and decreased bile cholesterol and phospholipid 
concentrations in female mice, which also evinced modest decreases in total cholesterol, LDL and 
CE concentrations when challenged with a diet enriched with cholesterol [141].     
The cholesterol-binding properties of StarD5 remain controversial: this protein has been reported 
to bind cholesterol and 25-hydroxycholesterol [142, 143], while other studies indicate primary and 
secondary bile acids as its preferred ligands [131,145-1457].    Unlike StarD4, the promoter region of 
StarD5 does not contain a sterol response element.  Instead, StarD5 expression appears to be 
increased in macrophages enriched in free cholesterol [130], due to activation of the endoplasmic 
reticulum stress response mediated by the transcriptional stress factor, XBP1; induction of 
endoplasmic reticulum stress is also associated with stabilisation of StarD5 mRNA, and with 
movement of StarD5 from the nucleus to cytosol and membranes [147].  Levels of StarD5 mRNA 
and protein are decreased in hepatic tissues from genetically obese rodents [133], and are thought 
to be concentrated in Kupffer cells within human liver [143-144; 147].  StarD5 is targeted by c-Jun N-
terminal kinase and cyclooxygenase-2, possibly as part of a protective stress response, within 
specialised epithelial Sertoli cells [148].  Overexpression of STARD5 in hepatocytes increased the 
free cholesterol content of intracellular membranes [143, 144]; in rodent hepatoma cells, STARD5 
overexpression did not alter cholesterol homeostasis, but increased the basal synthesis of 
triacylglycerol, promoted the incorporation of pre-formed fatty acids into this neutral lipid and 
stimulated the expression of Dgat1 [133].    
The cholesterol binding affinity of STARD6 is similar to that of STARD1/StAR in that it induces 
adrenal and gonadal steroidogenesis, although the protease-sensitive C-terminal is smaller than 
that of StAR [149].  Both STARD1 and STARD6 unfold and refold with similar (slow) kinetic 
patterns, and interact equally well with mitochondrial membranes [149].  Initially STARD6 was 
reported to be limited to male germ-line cells [84, 150, 151], but recent studies have shown that this 
protein is expressed in steroidogenic cells of the ovary, where it lies under the control of GATA4 and 
GATA6 transcription factors, and facilitates pregnenolone production [150].  Further, Chang and 
coworkers have reported STARD6 to be present in the brain, spinal cord and dorsal root ganglia, 
where it may play a role in the formation of neuroprotective steroids after excitotoxic brain injury 
[151-153].   
Since the majority of ORPs are found at membrane contact sites, there are few reports of cytosolic 
versions of this family of proteins.    However, two variants of ORP1 exist, which display different 
tissue expression patterns, intracellular localisation and functions [154]. The ‘short’ form of ORP1 
(ORP1S) is known to translocate from the cytosol to the nucleus after binding sterol, where it binds 
to LXR and enhances LXR-dependent transcription of apoE via the ME.1 and ME.2 enhancer 
elements of this gene [155]. Overexpression of ORP1s (together with ORP2) has also been shown to 
stimulate transport of sterol from the plasma membrane to lipid droplets, by enhancing plasma 
membrane to endoplasmic reticulum transport [156], and it is clear that even the ‘short’ variants of 
ORPs can cluster at membrane contact sites [157]. 
Sterol-binding proteins: endoplasmic reticulum and the trans-Golgi network 
The prototypic member of the ORP family, the 57kDa oxysterol binding protein (OSBP) regulates 
the movement of cholesterol from the endoplasmic reticulum to the trans-Golgi network at 
membrane contact sites between these organelles, driven by the transport of PI-4P in the opposite 
direction [106,107, 156-160].   This exchange of lipid is inhibited by 25-hydroxycholesterol, and also 
triggers recruitment of STARD11 (CERT) for sphingomyelin synthesis, demonstrating cross-talk 
between the ORP and START families of lipid trafficking proteins [156-160].   Depletion of VAMP-
associated proteins, VAPs (VAP-A, VAP-B) inhibits Golgi-mediated transport events, which are co-
ordinately regulated by the phosphatidylinositol/ phosphatidylcholine transfer protein, Nir2, 
together with OSBP and CERT, all of which interact with VAPs via the FFAT motif.  Notably, 
Mesmin et al (2013) recently described a four-step cycle, driven by PI-4P hydrolysis: the PH domain 
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tethers OSBP at the membrane, the FFAT motif enables sterol transfer via ORD, followed by 
retrograde transfer of PI-4P, and hydrolysis of PI-4P by the endoplasmic reticulum protein Sac1 
[161].   The OSBP controls the Golgi cholesterol level, which is essential for the correct localisation 
of GS28 and GS15 and effective coat protein complex (COP)-I vesicle transport: knockdown of 
OSBP results in cytosolic mis-localisation of intra-Golgi vSNAREs, GS28 and GS15, and reduces the 
amount of the Golgi enzyme, mannosidase II, a phenotype which can also be induced by depletion 
of cellular cholesterol [160].    Some of these properties of OSBP have apparently been exploited by 
RNA viruses, such as poliovirus and hepatitis C virus, which require PI 4-kinases and their effectors 
for replication [162].   
Overexpression of OSBP in hepatocytes, or injection of adenovirus expressing OSBP in mice, results 
in a marked increase in hepatic triglycerides, and increased output of VLDL (+70%), mediated via 
upregulation of SREBP-1 and increased expression of enzymes involved in fatty acid biosynthesis; 
by contrast, silencing of OSBP blocked insulin-induction of SREBP-1c, reducing triglyceride 
synthesis [163].    Suppression of OSBP in Chinese hamster ovary cells or macrophages increases the 
expression of ABCA1, via stabilisation of the ABCA1 protein, an effect that was abrogated by a 
mutation in the ORD [164].    Mutants of OSBP in Drosophila exhibit male-sterility and defects in 
spermatid packaging into its own membrane, suggesting sterol trafficking plays a key role in this 
process [165] and discussed further below.   
Another ORP known to influence the intra-Golgi vSNARE protein GS28 is ORP7, which is enriched in 
the gastrointestinal tract, and interacts with GATE-16, a regulator of GS28 function and stability.  
Knockdown of ORP7 increased the levels of GS28 protein (+40%), while ORP7 overexpression 
achieved the reverse (-25%) by proteasomal degradation; equally, cells treated with the ORP7 
ligand, 25-hydroxycholesterol, displayed destabilised GS28 [166].  Overexpression of ORP7 also led 
to the formation of vacuolar structures, autophagosomes, which stained positive for GATE-16 [166].   
Lastly, ORP9L is known to interact with the Golgi and trans-Golgi network via its PH domain and 
the endoplasmic reticulum via interactions with VAP-A, and is thought to aid in the maintenance of 
the early secretory pathway [167, 168].  The function of ORP9L seems similar to that of OSBP, in 
that both can facilitate PI-4P dependent cholesterol transport between liposomes; ORP9 can also 
interact with ORP11 as a dimer.  Silencing of ORP9L causes fragmentation of Golgi and build-up of 
cholesterol within endosomes and lysosomes [167, 168].  By contrast, ORP9S, which lacks the PH 
domain, acts as a dominant negative variant, and overexpression of this protein inhibits protein 
transport and cell growth [167, 168].   More recently, Liu and Ridgway (2014) have demonstrated 
that both ORP9L and ORP9S bind sterol and PI-4P, and that sequestration of Golgi PI-4P by ORP9S 
may explain the growth inhibitory effects of this variant [169]. 
Sterol-binding proteins: endoplasmic reticulum and the plasma membrane 
As indicated above, ORP5 and ORP8, both tail-anchored ORPs integral to the endoplasmic 
reticulum, can transport phosphatidylserine from the endoplasmic reticulum to mitochondria at 
membrane contact sites [129].  The same combination of ORPs can also tether the endoplasmic 
reticulum to the plasma membrane, via the interaction of the PH domain with PI-4P in the plasma 
membrane [170].  Again, glycerophospholipids are exchanged between these bilayers, rather than 
sterol, such that PI-4P is delivered to the endoplasmic reticulum PI-4P phosphatase Sac1 for 
degradation, and the plasma membrane is enriched in phosphatidylserine [170].  ORP5 is also 
involved in endosomal cholesterol trafficking, via interaction with NPC-1 protein: knockdown of 
ORP5 triggers the build-up of cholesterol in the limiting membranes of late endosomes and 
lysosomes, and causes the mislocalisation of trans-Golgi resident proteins to endosomal 
compartments [171].   
Notably, the expression of ORP5 is associated with invasion and poor prognosis in patients with 
pancreatic cancer [172, 173].    In some pancreatic cancers, strong expression of ORP5 augments the 
cholesterol biosynthesis pathway, via induction of SREBP-2 and its downstream target histone 
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deacetylase 5 (HDAC5), rendering invasion rate and growth susceptible to inhibition by statin 
inhibitors of HMG CoA reductase [172, 173].   This finding may prove clinically significant, given the 
lack of current therapies with positive impact on this highly lethal disease [174]. High expression 
levels of ORP5 have also been linked to the metastatic potential of lung cancer cells, as 
overexpression increased lung cancer cell invasiveness, while knockdown achieved the reverse 
[175].  Notably, survival rates were significantly lower in patients with ORP-5 positive cancer: the 
median survival time of the ORP-5 negative group was longer than that of the ORP-5 positive group 
by 8.9 months [175].    
The C-terminal ORD of ORP8 anchors this protein to the endoplasmic reticulum, binds 25-
hydroxycholesterol, and ORP8 known to interact with the nuclear porin Nup62 thereby reducing 
the levels of nuclear SREBP-1, SREBP-2 and their downstream target genes [176].  Thus, hepatic 
overexpression of ORP8 in Huh7 cells reduced cholesterol biosynthesis from radiolabelled acetate, 
and adenoviral administration of ORP8 decreased serum and hepatic levels of cholesterol, 
phospholipids and triglycerides in serum and liver tissues in mice [176].   Treatment of HepG2 cells 
with 25-hydroxycholesterol, or overexpression of ORP8, also slows the cell cycle, causing cells to 
remain longer in the G2/M phase, by recruitment of SPAG5 (Homo sapiens sperm associated 
antigen 5)/Astrin to the endoplasmic reticulum during interphase [177].   
In macrophages, the interaction of ORP8 with Nup62 is thought to suppress migration and suppress 
microtubule formation [178], and overexpression of ORP8 is associated with decreased expression 
of ABCA1 and attenuated cholesterol efflux to apoA-I in murine macrophages [179].  Indeed, 
silencing of ORP8 in human macrophages enhances ABCA1 transcription, by negating the 
suppressive effects of ORP8 at the LXRE and E-box sites within the promoter region of ABCA1.   In 
good agreement, ORP8 knockout in macrophages resulted in lower susceptibility to foam cell 
formation, decreased output of inflammatory cytokines, and reduced levels of differentiation 
markers [178, 179].   
Mice lacking ORP8  showed increased levels of HDL cholesterol in the bloodstream [180], 
suggesting increased hepatic expression of ABCA1, while LDL receptor-/- mice transplanted with 
ORP8-/- bone marrow displayed higher levels of VLDL-cholesterol (+50%) but no increase in HDL-C 
when fed a high fat/high cholesterol diet [181].  However, LDL receptor-/- mice transplanted with 
ORP8-/- bone marrow developed smaller atherosclerotic lesions (-20%), despite a modest increase in 
macrophage content, compared with wild type transplanted controls, on the same atherogenic diet 
[180].   In human coronary atherosclerotic lesions, ORP8 co-localises with CD68(+) macrophages in 
the shoulder regions of the plaque, and is significantly increased (2.7-fold) compared with healthy 
arterial tissue [180], suggesting that ORP8 may be a good therapeutic target for prevention of 
disease.  In support of this miR-143b, which down-regulates ORP8, is upregulated in hepatic tissues 
in genetic and dietary murine models of obesity, characterised by impaired insulin-signalling to AKT 
and glucose metabolism [182].  Importantly, repression of ORP8 also limits insulin-stimulation of 
AKT, highlighting the miR-143b-ORP8 pathway as an important target in treatment of diabetes and 
cardiovascular disease [182].   
Sterol-binding proteins: endosomes, late endosomes and the ER 
Members of the ORP and START families are involved in late endosome-endoplasmic reticulum 
membrane contact sites, together with a newly discovered third family of sterol-binding proteins, 
conserved between yeast and man, called the lipid transfer protein anchored at membrane contact 
sites (Lam) proteins [183, 184].    
The sterol sensor ORP1L has been shown to be involved in the NPC2-dependent transport of 
endosomal LDL cholesterol to a specific pool within the endoplasmic reticulum, destined for 
esterification into lipid droplets, and that mutations in OSBP1LA contribute to extremely low levels 
of serum HDL [106, 185, 186].  It is known that endosomes fated for eventual fusion have to be 
transported intracellularly before tethering to initiate contact, and ORP1L is part of a multi-protein 
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complex (RAB7-RILP-ORP1L) involved in late endosomal transport and tethering [186].  Here, 
ORL1L acts as a cholesterol-sensing switch controlling the interactions between RILP-HOPS-
p150(Glued).  The RAB7-RILP-ORP1L complex recruits the dynein motor and HOPS protein 
complex, and regulates microtubule minus-end transport and fusion, both key events in endosomal 
fusion [185, 186].  Further, it seems ORP1L and the other member of the STARD1 subfamily, 
STARD3, mark distinct late endosomes [187].  ORP1L is localised to late endosomes containing 
NPC1, which deliver cholesterol to the endoplasmic reticulum, while STARD3 is present in a distinct 
population containing the cholesterol transporter ABCA3 which can recycle cholesterol to the 
plasma membrane [187].   
STARD3, also called Metastatic Lymph Node 64 (MLN64) is co-amplified with the oncogene ERBB2 
in human breast carcinoma, and has two distinct conserved cholesterol binding regions: the 
classical C-terminal START domain and a region of four transmembrane helices with three short 
intervening loops, termed the N-terminal (MENTAL) domain [36, 39, 93, 188 ].   STARD3 also has a 
close paralogue, the STARD3 N-terminal like (MENTHO) protein, and recent data suggest that both 
are anchored on the limiting membrane of late endosomes where they interact with endoplasmic 
reticulum-anchored VAP-A and VAP-B proteins to form membrane contact sites which may 
influence endosome dynamics [189, 190].   STARD3 undergoes endocytosis from the plasma 
membrane to late endocytic compartments, although in cholesterol-laden cells, this movement is 
inhibited, and STARD3 becomes trapped at the edges of cholesterol-enriched lysosomes [39].  
Knockdown of STARD3 disperses late endosomes to the cell periphery, decreases the association of 
these organelles with actin and impairs the fusion of late endocytic vesicles.  Equally, 
overexpression of STARD3 increased the association of actin with late endosomes, and stimulated 
the accumulation of sterol in these organelles [39].  STARD3 can also enhance the movement of 
lysosomal cholesterol to mitochondria and stimulate steroidogenesis, an effect which is enhanced 
by removal of N-terminal sequences [36, 191].   
The expression of STARD3 mRNA and protein are repressed during macrophage differentiation, 
and by sterol accumulation, but stimulated by the hypocholesterolaemic agent LY295427 in 
macrophages, suggesting that STARD3 is a SREBP target [122].   Overexpression of STARD3 in 
human macrophages induces the expression of ABCA1, enhances efflux of cholesterol to apoA-I and 
inhibits lipogenesis, and blocks cholesterol ester deposition following exposure to modified LDL, 
suggesting an anti-atherogenic phenotype [192].  Hepatic levels of StarD3 protein decreased in 
genetic obesity, suggesting a link with lipid storage or lipoprotein export from the liver [133].   
Genetic deletion of the START domain of STARD3 in mice induced only modest changes in lipid 
metabolism in mice [193].  However, overexpression of StarD3 increases bile acid synthesis via 
CYP27A1 in primary rat hepatocytes [127] and in rat hepatoma cells overexpression of StarD3 
increased lipidation of exogenous apoA-I, and facilitated de novo biosynthesis of neutral lipids [133].   
Notably, the functional role of STARD3 in promoting steroidogenesis, and the overexpression of 
STARD3 in human breast carcinomas, led to the suggestion that this protein could promote 
intraneoplastic autonomous steroidogenesis and contribute to tumour growth.  High levels of 
STARD3 are also found in neoplastic prostatic tumours, correlating with stage of disease and short 
relapse time [194].  Cai et al (2010) have also described an association between elevated STARD3 
and poor prognosis and overall survival in breast cancer patients, possibly via regulation of cell 
proliferation and adhesion [195].   
Finally, ORP6, which is a target for LXRs and is regulated by cholesterol loading in cells, and by a 
Western diet in animal models, also appears to associate with the endolysosomal network [196].  
Overexpression of ORP6 enhances endosomal trafficking and cholesterol efflux in macrophages 
and hepatocytes, while knockdown of ORP6 triggers aberrant endosome clusters, enriched in free 
cholesterol, and reduced cholesterol esterification at the endoplasmic reticulum [196].   Levels of 
ORP6 correlate direct with plasma HDL concentrations, are repressed by miR-33 and miR-27b, and 
are reduced in human atherosclerotic plaques [196].   
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Sterol-binding proteins: ER and lipid droplets 
Recent data suggests that cholesterol metabolism is also regulated by ORP2 [190], which possesses 
ORD and FFAT motifs, but not a PH domain.  This protein targets lipid droplets and, when 
complexed with VAP, decorates endoplasmic reticulum structures with lipid droplets attached to 
them, facilitating the synthesis (and inhibiting the lipolysis) of triglycerides in hepatic cells [197].   
Whether ORP2 plays a similar role in promoting the formation of lipid droplets of CE is not known, 
but knockdown of ORP2 in adrenocortical cells reduces the production of some steroids, including 
progesterone, 11-deoxycortisol and cortisol, but enhances the production of androgens and 
estrogens [198].  Loss of ORP2 is also associated with reduced levels of 22-hydroxycholesterol and 
7-ketocholesterol, both of which bind to ORP2; ORP2 also binds to LXR, facilitating recruitment to 
the CYP11B1 promoter in response to cAMP, and is required for the expression of a number of LXR 
targets, including ABCA1 [198].   
Frameshift mutations in OSBPL2, which encodes ORP2, cause a form of autosomal dominant 
hearing loss (DFNA67) [199, 200], although whether this effect is related to its sterol-
binding/transfer properties remains unknown.  The genetics of nonsyndromic congenital hearing 
loss are complex: to date more than 125 deafness loci have been identified, 58 of which cause 
autosomal dominant hearing loss (DFNA), 63 cause autosomal recessive inherited hearing loss 
(DFNB) and 4 are X-linked [201].   This reflects the large number of genes involved in inner-ear 
function, with mutations affecting adhesion of hair cells, intracellular transport and cytoskeletal 
function, and neurotransmitter release all known to contribute to malfunction of the cochlea and 
inner ear [201].  Mutated OSBPL2 was discovered as a novel locus causing onset of hearing loss in 
childhood, progressing to profound deafness in adulthood [199, 200].  Wild type ORP2 encodes a 
protein located in inner and outer hair cell stereocilia, where it interacts with diaphanous 
homologue 1 (DIAPH1), a Rho effector protein that regulates cytoskeletal dynamics.   A mutated 
(truncated) form of ORP2 may interfere with cytoskeletal function, which is critical for the structure 
of stereocilia; since ORP2 also binds PI-3P, ORP2 may also be involved in creating or sustaining the 
polarity of hair cells [199, 200].   It remains an intriguing possibility that cholesterol metabolism may 
play a role in hair cell function and hearing loss: Malgrange et al (2015) recently speculated that 
cholesterol homeostasis may contribute to sensorineural hearing loss [202].   
ORP4, which displays the highest degree of similarity with OSBP, has two variants: the long form 
ORP4L) has both a PH and an oxysterol binding domain, while the short form (ORP4S) lacks the the 
PH domain and part of the ORD.  ORP4S colocalises with vimentin, causing the intermediate 
filament network to aggregate, and when overexpressed limits (-40%) esterification of cholesterol 
derived from endocytosis of LDL [203].  The short form of ORP4 inhibits the replication of hepatitis 
C virus in liver cells, but promotes the formation of lipid droplets in this context [204].  Notably, 
genetic deletion of ORP4 causes male infertility, due to severe oligo-astheno-teratozoospermia 
(OAT) (low sperm number, motility and abnormal morphology) [205].    Approximately 60% of OAT 
is diagnosed as idiopathic, implying the contribution of genetic abnormalities, although these have 
proved elusive to date.  Loss of ORP4 in mice causes a marked reduction in sperm count, due to 
apoptosis of post-meiotic spermatids; abnormal sperm morphology is also observed, due to defects 
in the post-meiotic differentiation of germ cells, causing the build-up of deformed spermatids in the 
seminiferous tubules of ORP4-/- mice.    The abnormal distribution of mitochondria in OPR4-/- sperm 
may contribute to low sperm motility [205], and although total cholesterol mass was not altered in 
the testis of wild type and knockout mouse, it remains possible that subcellular cholesterol 
distribution could be affected.  This concept is supported by studies in Drosophila melanogaster, 
where mutations in the single homologue of OSBP and ORP4, CG6708, cause abnormal sterol 
distribution during ‘germ cell individualisation’ and sterility can be rescued by treatment with 
cholesterol or 7-dehydrocholesterol [207].   
Sterol-binding proteins: microtubules and Golgi 
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The cholesterol-binding protein ORP10 possesses both ORD and PH domains, and is found 
associated with microtubules and with Golgi membranes [207].  Knockdown of ORP10 is associated 
with increased output of apoB100 by human (Huh7) hepatocytes, and reduced levels of intracellular 
apoB100, indicating a repressive role for ORP10 in the output of VLDL [207].  Polymorphisms in the 
OSBP10 gene are associated with elevated LDL cholesterol, and with peripheral arterial disease 
[208].   
TARGETING STEROL-BINDING PROTEINS 
The increasing numbers of roles assigned to sterol-binding proteins has led to interest in identifying 
or developing small molecules which can bind and modify the function of these proteins.  Chitrala 
and Yeguvapalli (2014) have recently described a ligand-based virtual screening approach to 
identify molecules which inhibit the steroidogenic function of STARD3 [209] and the dietary 
carotenoid lutein has recently been described as a high affinity ligand for STARD3 (Kd=0.45M) 
[210]; no impact on cholesterol metabolism has, as yet, been reported.    
By contrast, a number of natural compounds which bind ORPs, termed ‘ORPphilins’ have been 
identified, and it is likely that these molecules will be useful in deciphering the cellular functions and 
roles of ORPs in human disease.  Some of these compounds, such as OSW-1 cephalostatin, 
ritterazine B and schweinfurthin A, are currently under development as anti-cancer drugs, but have 
also proved useful as inhibitors of enterovirus replication [211-214].   For example, schweinfurthins 
inhibit trans-Golgi network trafficking by binding to OSBP and inhibit proliferation of PTEN 
deficient cancer cells by blocking phosphorylation of AKT [212].  Itraconazole is an anti-fungal agent 
with anti-cancer activity, and is known to target OSBP and ORP4L, inhibiting enteroviral replication 
by disrupting the membrane changes needed for viral replication organelle formation [213].   
FUTURE DIRECTIONS 
It is becoming increasingly clear that sterol-binding sensors, exchangers and transporters contribute 
to regulation of cellular cholesterol homeostasis, and that mutations in a number of these proteins 
cause disease (summarised in Figure 1C).   Congenital lipoid hyperplasia, male sterility and 
autosomal dominant hearing loss are caused by loss-of-function mutations in StAR, OSBP and 
ORP4, and ORP2, respectively, while studies in mice suggest that knockdown of ORP8 may help to 
prevent the development of atherosclerotic lesions and diabetes.    Loss of StarD4 may aid weight 
loss and reduce serum lipid concentrations, while knockdown of ORP10 could limit the output of 
triglyceride-rich lipoproteins and modulate peripheral arterial disease.    Enhanced expression of 
ORP5 is linked to poor outcome in pancreatic cancer, and co-amplification of STARD3 with ERBB2 is 
linked with breast carcinoma.  By contrast, cellular studies indicate that overexpression of StAR, 
STARD3, STARD4 ORP1L, ORP2 or ORP6 could help to reduce cholesterol accumulation and/or 
inflammation within vascular or hepatic tissues, and enhanced expression of ORP4S can limit 
replication of hepatitis C.   However, much remains to be understood about their differing modes of 
action and the polymorphisms which affect their function; the extent to which differing family 
members can compensate for genetic deletion of another also demands attention, as does the 
crosstalk between family members, and between the distinct ORP and START families of proteins.     
Declarations of interest and Funding information An international patent application 
(PCT/GB2014/052585) has been filed on behalf of Glasgow Caledonian University, relating to 
cholesterol modulation in macrophages by a transport protein.  No other conflicting interests, 
commercial, intellectual, or otherwise, exist relating to this manuscript.  The authors are indebted 
to Dr Richard William Turnbull for his aid with illustrations.  Research cited within this article, from 
the laboratory of the corresponding author, was funded by the British Heart Foundation 
(PG/07/039/22873; PG04/063/17186), British Skin Foundation (807S), Diabetes UK (11/0004333), and 






1. Cortes VA, Busso D,Maiz A, Arteaga A, Nervi F, Rigotti A. (2014). Physiological and 
pathological implications of cholesterol.  Front Biosci 19, 416-428. 
2. Rogers MA, Liu J, Song BL, Li BL, Chang CC, Chang TY (2015) Acyl-CoA:cholesterol 
acyltransferases (ACATs/SOATs): enzymes with multiple sterols as  substrates and as 
activators.  J Steroid Biochem Mol Biol 151, 102-107. 
3. Khor VK, Shen WJ, Kraemer FB (2013) Lipid droplet metabolism.  16(6), 632-637. 
4. Ye, J., DeBose-Boyd, R.A. (2011) Regulation of cholesterol and fatty acid synthesis. Cold 
Spring Harb Perspect Biol 3(7). 
5. Eberle, D., Hegarty, P., Bossard, P., Ferre, P., Foufelle, FF (2004) SREBP transcription 
factors: master regulators of lipid homeostasis. Biochimie 86(11), 839-48. 
6. Sato, R. (2010) Sterol metabolism and SREBP activation. Arch Biochem Biophys  501(2), 
177-81. 
7. Giandomenico, V., Simonsson, M., Gronroos, E., Ericsson, J. (2003) Coactivator-dependent 
acetylation stabilizes members of the SREBP family of transcription factors. Mol Cell Biol 
23(7), 2587-99. 
8. Walker, A.K., Yang, G., Jiang, K., Ji, J.Y., Watts, J.L., Purushotham, A., Boss, O., Hirsch, 
M.L., Ribich, S., Smith, J.J., Israelian, K., Westphal, C.H., Rodgers, J.T., Shioda, T., Elson, 
S.L., Mulligan, P., Najafi-Shoushtari, H., Black, J.C., Thakur J.K., Kadyk, L.C., Whetstine, 
J.R., Mostoslavsky, R., Puigserver, P., Li, X., Dyson, N.J., Hart, A.C., Naar, A.C. (2010) 
Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol 
regulator SREBP. Genes Dev 24(13), 1403-17. 
9. Stohr, R., Mavilio, M., Marino, A., Casagrande, V., Kappel, B., Mollmann, J., Menghini, R., 
Melino, G., Federici, M. (2015) ITCH modulates SIRT6 and SREBP2 to influence lipid 
metabolism and atherosclerosis in ApoE null mice. Sci Rep 5, 9023. 
10. Hirano, Y., Yoshida, M., Shimizu, M., Sato, R. (2001) Direct demonstration of rapid 
degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-
proteasome pathway. J Biol Chem 276, 36431-7. 
11. Hirano, Y., Murata, S., Tanaka, M., Shimizu, M., Sato, R. (2003) Sterol regulatory element-
binding proteins are negatively regulated through SUMO-1 modification independent of the 
ubiquitin/26 S proteasome pathway. J Biol Chem 278(19), 16809-19. 
12. Shao, W.,  Espenshade, P.J. (2014) Sterol regulatory element-binding protein (SREBP) 
cleavage regulates Golgi-to-endoplasmic reticulum recycling of SREBP cleavage-activating 
protein (SCAP). J Biol Chem 289(11), 7547-57. 
13. Goldstein, J.L., R.A. DeBose-Boyd, and M.S. Brown, Protein sensors for membrane sterols. 
Cell, 2006. 124(1): p. 35-46. 
14. Goldstein, J.L., Brown, M.S. (1990) Regulation of the mevalonate pathway. Nature  
343(6257), 425-30. 
15. Ness GC (2015) Physiological feedback regulation of cholesterol biosynthesis: role of 
translational control of hepatic HMG CoA reductase and possible involvement of 
oxylanosterols.  Biochim Biophys Acta 1851(5), 667-673. 
16. Song, B.L., Javitt, N.B., DeBose-Boyd, R.A. (2005) Insig-mediated degradation of HMG CoA 
reductase stimulated by lanosterol, an intermediate in the synthesis of cholesterol. Cell 
Metab  1(3), 179-89. 
17. Olkkonen, V.M., Beaslas, O., Nissila, E. (2012) Oxysterols and their cellular effectors 
Biomolecules 2(1), 76-103. 
18. Song, B.L., DeBose-Boyd, R.A. (2004) Ubiquitination of 3-hydroxy-3-methylglutaryl-CoA 
reductase in permeabilized cells mediated by cytosolic E1 and a putative membrane-bound 
ubiquitin ligase. J Biol Chem 279(27), 28798-806. 
17 
 
19. Mihaylova, M.M., R.J. Shaw, R.J. (2011), The AMPK signalling pathway coordinates cell 
growth, autophagy and metabolism. Nat Cell Biol 13(9), 1016-23. 
20. Rayner, K.J., Suarez, A., Davalos, A., Parathath, S., Fitzgerald, M.L., Tamehiro, N., Fisher, 
E.A., Moore, K.J., Fernandez-Hernando, C. (2010)  MiR-33 contributes to the regulation of 
cholesterol homeostasis. Science 328(5985), 1570-3. 
21. Adlakha, Y.K., Khanna, S., Singh, R., Singh, V.P., Agrawal, A., Saini, N (2013) Pro-apoptotic 
miRNA-128-2 modulates ABCA1, ABCG1 and RXRalpha expression and cholesterol 
homeostasis. Cell Death Dis 4, e780. 
22. Jeon TI, Osborne TF (2016) miRNA and cholesterol homeostasis.  Biochim Biophys Acta 
pii:S1388-1981(16)00006-8.  doi:10.1016/j.bbalip.2016.01.005. [Epub ahead of print] 
23. Di Marco DM, Fernandez ML (2015) The regulation of reverse cholesterol transport and 
cellular cholesterol homeostasis by microRNAs.  Biology (Basel) 4(3),494-511. 
24. Goldstein, J.L., Brown,M.S. (2009) The LDL receptor. Arterioscler Thromb Vasc Biol 29(4),  
431-8. 
25. Brown, M.S., Goldstein, J.L. (1986) A receptor-mediated pathway for cholesterol 
homeostasis. Science 232(4746), 34-47. 
26. Yu, X.H., Jiang, N., Yao, P.B., Zheng, S.L., Cayabyab, F.S., Tang, C.K. (2014) NPC1, 
intracellular cholesterol trafficking and atherosclerosis. Clin Chim Acta  429, 69-75. 
27. Vanier, M.T. (2015) Complex lipid trafficking in Niemann-Pick disease type C. J Inherit 
Metab Dis 38(1), 187-99. 
28. Soccio, R.E., Breslow, J.L. (2004) Intracellular cholesterol transport. Arterioscler Thromb 
Vasc Biol 24(7), 1150-60. 
29. Yang, H., Galea, A., Sytnyk, V., Crossley, M. (2012) Controlling the size of lipid droplets: lipid 
and protein factors. Curr Opin Cell Biol 24(4), 509-16. 
30. Du, X., Brown, A.J., Yang, H. (2015) Novel mechanisms of intracellular cholesterol transport: 
oxysterol-binding proteins and membrane contact sites. Curr Opin Cell Biol 35, 37-42. 
31. Garbarino, J., Pan, M., Chin, H.F., Lund, F.W., Maxfield, F.R., Breslow, J.L. (2012) STARD4 
knockdown in HepG2 cells disrupts cholesterol trafficking associated with the plasma 
membrane, ER, and ERC. J Lipid Res  53(12), 2716-25. 
32. Alpy, F., Tomasetto, C. (2005) Give lipids a START: the StAR-related lipid transfer (START) 
domain in mammals. J Cell Sci  118(Pt 13), 2791-801. 
33. Seedorf, U., Ellinghaus, P., Nofer, J.R. (2000)  Sterol carrier protein-2. Biochim Biophys 
Acta, 2000. 1486(1), 45-54. 
34. Ning, Y., Bai, Q., Lu, H., Pandak, W.M., Zhao, F., Chen, S., Ren, S., Yin, L. (2009) 
Overexpression of mitochondrial cholesterol delivery protein, StAR, decreases intracellular 
lipids and inflammatory factors secretion in macrophages. Atherosclerosis 204(1), 114-20. 
35. Mesmin, B., Pipalia, N.H., Lund, F.W., Ramlall, T.F., Sokolov, A., Eliezer, D., Maxfield, F.R. 
(2011) STARD4 abundance regulates sterol transport and sensing. Mol Biol Cell 22(21), 
4004-15. 
36. Zhang, M., Liu, N.K., Dwyer, L.K., Christenson, L.K., Fujimioto, T., Martinez, F., Comly, M., 
Hanover, J.A., Blanchett-Mackie, E.J., Strauss, J.F. 3rd (2002) MLN64 mediates mobilization 
of lysosomal cholesterol to steroidogenic mitochondria. J Biol Chem 277(36), 33300-10. 
37. Lebrand, C., Corti, M., Goodson, H., Cosson, P., Cavalli, V., Mayran, N., Faure, J., 
Gruenberg, J. (2002) Late endosome motility depends on lipids via the small GTPase Rab7. 
EMBO J 21(6), 1289-300. 
38. Kanerva, K., Uronen, R.L., Blom, T., Li, S., Bittman, R., Lappalainen, P., Peranen, J., Raposo, 
G., Ikonen, E. (2013) LDL cholesterol recycles to the plasma membrane via a Rab8a-
Myosin5b-actin-dependent membrane transport route. Dev Cell 27(3), 249-62. 
39. Holtta-Vuori M, Alpy F, Tanhuanpaa K, Jokitalo E, Mutka AL, Ikonen E (2005) MLN64 is 




40. Lehto, M., Mayranpaa, M.I., Pellinen, T., Ihalmo, P., Lehtonen, S., Kovanan, P.T., Groop, 
P.H., Ivaska, J., Olkkonen, V.M. (2008) The R-Ras interaction partner ORP3 regulates cell 
adhesion. J Cell Sci 121(Pt 5), 695-705. 
41. Korach-Andre, M., Gustafsson, J.A. (2015) Liver X receptors as regulators of metabolism. 
Biomol Concepts 6(3), 177-90. 
42. Zhao, C., Dahlman-Wright, K. (2010) Liver X receptor in cholesterol metabolism. J 
Endocrinol, 204(3), 233-40. 
43. Gabbi C, Warner M, Gustafsson JA (2014) Action mechanisms of Liver X receptors.  Biochem 
Biophys Res Commun 446(3), 647-650. 
44. Miserez, A.R., Muller, P.Y., Barella, L., Barella, S., Staehelin, H.B., Leitersdorf, E., Kark, J.D., 
Friendlander, Y. (2002) Sterol-regulatory element-binding protein (SREBP)-2 contributes to 
polygenic hypercholesterolaemia. Atherosclerosis 164(1), 15-26. 
45. Lagace, T.A. (2014) PCSK9 and LDLR degradation: regulatory mechanisms in circulation 
and in cells. Curr Opin Lipidol 25(5), 387-93. 
46. Zhang, L., Reue, K., Fong, L.G., Young, S.G., Tontonez, P. (2012) Feedback regulation of 
cholesterol uptake by the LXR-IDOL-LDLR axis. Arterioscler Thromb Vasc Biol 32(11), 2541-
6. 
47. Rye KA, Barter PJ (2014) Regulation of high-density lipoprotein metabolism.  Circ Res 
114(1), 143-156. 
48. Wang S, Smith JD (2014) ABCA1 and nascent HDL biogenesis.  Biofactors 40(6):547-554. 
49. Getz, G.S., Reardon, C.A. (2009) Apoprotein E as a lipid transport and signaling protein in 
the blood, liver, and artery wall. J Lipid Res 50, S156-61. 
50. Gupta, S., Pandak, W.M., Hylemon, P.B. (2002) LXR alpha is the dominant regulator of 
CYP7A1 transcription. Biochem Biophys Res Commun 293(1), 338-43. 
51. Stender, S., Frikke-Schmidt, R., Nordestgaard, B.G., Tubjaerg-Hansen, A. (2014)The 
ABCG5/8 cholesterol transporter and myocardial infarction versus gallstone disease. J Am 
Coll Cardiol, 63(20), 2121-8. 
52. Li G, Gu HM, Zhang DW (2013) ATP-binding cassette transporters and cholesterol 
translocation.  IUMBMB Life 65(6),505-512. 
53. Sawamura T, Kakino A, Fujita Y (2012) LOX-1: a multiligand receptor at the cross roads of 
response to danger signals.  Curr Opin Lipidol 23, 439-445.  
54. Kzhyshkowska J, Neyen C, Gordon S. (2012) The role of macrophage scavenger receptors in 
atherosclerosis. Immunobiology 217, 492-502. 
55. Adamson S, Leitinger N. (2011) Phenotypic modulation of macrophages in response to 
plaque lipids.  Curr Opin Lipidol 22, 335-342. 
56. Andres V, Pello O, Silvestre-Roig, C. (2012) Macrophage proliferation and apoptosis in 
atherosclerosis.  Curr Opin Lipidol 23, 429-438.   
57. Nakashima H, Ogawa Y, Shono S, Kinoshita M, Nakashima M, Sato A, Ikarashi M, Seki S. 
(2013) Activation of CD11b+ Kupffer cells/macrophages as a common cause for 
exacerbation of TNF/Fas-ligand-dependent hepatitis in hypercholesterolaemic mice.  PloS 
One 8:e49339.  
58. Ioannu GN, Haigh WG, Thorning D, Savard C. (2014) Hepatic cholesterol crystals and crown-
like structures distinguish NASH from simple steatosis.  J Lipid Res 54, 1326-1334. 
59. Ioannou GN, Van Rooyen DM, Savard C, Haigh WC, Yeh MM, Teoh NC, Farrell GC. (2015) 
Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer 
cell crown-like structures during resolution of NASH.  J Lipid Res 56, 277-285.  
60. Pelton K, Krieder J, Joiner D, Freeman MR, Goldstein SA, Solomon KR. (2012) 
Hypercholesterolaemia promotes an osteoporotic phenotype.  Am J Pathol 181, 928-936. 
61. Sjogren U, Mukohyama H, Roth C, Sundqvist G, Lerner UH (2002) Bone-resorbing activity 
from cholesterol-exposed macrophages due to enhanced expression of interleukin-1 alpha. 
J Dent Res 81: 11-16. 
19 
 
62. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. 
(1999) Stimulation of bone formation in vitro and in rodents by statins.  Science 286, 1946-
1949. 
63. Poehling GG, Adair DM, Haupt HA. (1984) Erheim-Chester disease. A case report. Clin 
Orthop Relat Res 185:241-244.   
64. Plantier L, Besnard V, Xu Y, Ikegami M, Wert SE, Hunt AN, Postle AD, Whitsett JA.  (2012) 
Activation of sterol-response element-binding proteins (SREBP) in alveolar type II cells 
enhances lipogenesis causing pulmonary lipotoxicity.  J Biol Chem 287,10099-10114.  
65. Malur A, Kavuru MS, Marshall I, Barna BP, Huizar I, Karnekar R, Thomassen MJ. (2012) 
Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid 
homeostasis. Respir Res 13:4. 
66. Cruz PM, Mo H, McConathy WJ, Sabnis N, Lacko AG (2013) The role of cholesterol 
metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, 
relevant to future cancer therapeutics.  Front Pharmacol 4,119. 
67. Kuzu OF, Noory MA, Robertson GP (2016) The role of cholesterol in cancer.  Cancer Res. 
76(8), 2063-2070. 
68. Chushi L, Wei W, Kangkang X, Yongzeng F, Ning X, Xiaolei C (2016) HMGCR is up-regulated 
in gastric cancer and promotes the growth and migration of the cancer cells.  Gene Pii, 
S0378-1119(16)30288-8. Doi:10.1016/j.gene.2016.04.029 [Epub ahead of print] 
69. Du Q, Wang Q, Fan H, Wang J, Liu X, Wang H, Wang Y, Hu R (2016) Dietary cholesterol 
promotes AOM-induced colorectal cancer through activating the NLRP3 inflammasome.  
Biochem Pharmacol 105, 42-54. 
70. Kubtka P, Kruzliak P, Rotrekl V, Jelinkova S, Mladosievicova B (2014) Statins in oncological 
research: from experimental studies to clinical practice.  Crit Rev Oncol Hematol 92(3), 296-
311. 
71. Lo Sasso G, Bovenga F, Murzilli S, Salvatore L, Di Tullio G, Martelli N, Di’Orazio A, Rainaldi 
S, Vacca M, Mangia A, Palasciano G, Moschetta A (2013) Liver X receptors inhibit 
proliferation of human colorectal cancer cells and growth of intestinal tumours in mice.  
Gastroenterology 144(5), 1497-1507. 
72. Chou JL, Huang RL, Shay J, Chen LY, Lin SJ, Yan PS, Chao WT, Lai YH, Lai YL, Chao TK, Lee 
CI, Tai CK, Wu SF, Nephew KP, Huang TH, Lai HC, Chan MW (2015) Hypermethylation of 
the TGF-
Epigenet 7(1), 1. 
73. Zhang L, Jiang M, Shui Y, Chen Y, Wang Q, Hu W, Ma X, Li X, Liu X, Cao X, Liu M, Duan Y, 
Han J (2013) DNA topoisomerase II inhibitors induce macrophage ABCA1 expression and 
cholesterol efflux – an LXR-dependent mechanism. Biochim Biophys Acta 1831(6), 1134-
1145. 
74. Xue-Shan Z, Juan P, Qi W, Zhong R, Li-Hong P, Zhi-Han T, Zhi-Sheng J, Gui-Xue W, Lu-
Shan L (2016) Imbalanced cholesterol metabolism in Alzheimer’s disease.  Clin Chim Acta 
456, 107-114. 
75. Cao G, Bales KR, DeMattos RB, Paul SM (2007) Liver X receptor-mediated gene regulation 
and cholesterol homeostasis in brain: relevance to Alzheimer’s disease therapeutics.  Curr 
Alzheimers Res 4, 179-184. 
76. Moehle MS, West AB (2015) Immune activation in Parkinson’s disease: foe and ally? 
Neuroscience 302, 59-73. 
77. Leoni V, Caccia C (2014) Study of cholesterol metabolism in Huntington’s disease.  Biochem 
Biophys Res Commun 446, 697-701. 
78. Millat, G, Marcais C, Tomasetto C, Chikh K, Fensom AH, Harzer K, Wenger DA, Ohno K, 
Vanien MTV (2001) Niemann-Pick C1 disease: correlations between NPC1 mutations, levels 
of NPC1 protein, and phenotypes emphasize the functional significance of the putative 
20 
 
sterol-sensing domain and of the cysteine-rich luminal loop.  Am J Hum Genet 68, 1373-
1385. 
79. Courtney R, Landreth GE (2016) LXR regulation of brain cholesterol: from development to 
disease.  Trends Endocrinol Metab 27(6), 404-414. 
80. Zyss J, Behin A, Couvert P, Bouhour F, Sassolas A, Kolev I, Denys V, Vial C, Lacour A, Carrie 
A, Stojkovic T. (2012) Clinical and electrophysiological characteristics of neuropathy 
associated with Tangier disease.  J Neurol 259, 1222-1226. 
81. Prinz WA (2007) Non-vesicular sterol transport in cells.  Prog Lipid Res 46, 297-314. 
82. Lev S (2010) Non-vesicular lipid transport by lipid-transfer proteins and beyond.  Nat Rev 
Mol Cell Biol 11, 739-750. 
83. Klipsic D, Landrock D, Martin GG, McIntosh AL, Landrock KK, Mackie JT, Schroeder F, Kier 
AB (2015) Impact of SCP-2/SCP-x gene ablation and dietary cholesterol on hepatic lipid 
accumulation.  Am J Physiol Gastrointest Liver Physiol 309(5), G387-99. 
84. Alpy, F, Tomasetto, C (2005) Give lipids a START: the StAR-related lipid transfer (START) 
domain in mammals. J Cell Sci 118(Pt 13), 2791-801.  
85. Tsujishita, Y, Hurley,J.H. (2000) Structure and lipid transport mechanism of a StAR-related 
domain. Nat Struct Biol 7(5): p. 408-14. 
86. Roderick, S.L.,Chan, W.W., Agate, D.S., Olsen, L.R., Vetting, M.W., Rajashankar, K.R., 
Cohen, L.E. (2002) Structure of human phosphatidylcholine transfer protein in complex 
with its ligand. Nat Struct Biol 9(7): p. 507-11. 
87. Romanowski, M.J., Soccio, R.E., Breslow, J.L., Burley, S.K. (2002) Crystal structure of the 
Mus musculus cholesterol-regulated START protein 4 (StarD4) containing a StAR-related 
lipid transfer domain. Proc Natl Acad Sci U S A 99(10), 6949-54. 
88. Kudo, N., Kumagai, K., Tamishige,  
N., Tamaji, T., Wakatsuki, S., Nishijima, M., Hanada, K., Kato, R. (2008) Structural basis for 
specific lipid recognition by CERT responsible for nonvesicular trafficking of ceramide. Proc 
Natl Acad Sci U S A 105(2), 488-93. 
89. Thorsell, A.G., Lee, W.H., Persson, C., Siponen, M.I., Nilsson, M., Busam, R.D., Kotenyova, 
T., Schuler, H., Lehto, L (2011) Comparative structural analysis of lipid binding START 
domains. PLoS One 6(6), e19521. 
90. Lin, D., Sugawara T., Strauss, J.F. 3rd, Clark, B.J., Stocco, D.M., Saenger, P., Rogol, A., Miller, 
W.L. (1995) Role of steroidogenic acute regulatory protein in adrenal and gonadal 
steroidogenesis. Science 267(5205), 1828-31. 
91. Clark, B.J., Wells, J., King, S.R., Stocco, D.M. (1994) The purification, cloning, and 
expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse 
Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR). J 
Biol Chem 269(45), 28314-22. 
92. Stocco, D.M. (1998) A review of the characteristics of the protein required for the acute 
regulation of steroid hormone biosynthesis: the case for the steroidogenic acute regulatory 
(StAR) protein. Proc Soc Exp Biol Med 217(2): p. 123-9. 
93. Alpy, F., Stoeckel, M.E., Dierich, A., Escola, J.M., Wendling, C., Chenard, M.P., Vanier, M.T., 
Grunenberg, J., Tomasetto, C., Rio, M.C. (2001) The steroidogenic acute regulatory protein 
homolog MLN64, a late endosomal cholesterol-binding protein. J Biol Chem 276(6), 4261-9. 
94. Soccio RE, Adams RM, Romanowski MJ, Schayek E, Burley SK, Breslow JL (2002) The 
cholesterol-regulated StarD4 gene encodes a StAR-related lipid transfer protein with two 
closely related homologues, StarD5 and StarD6.  Proc Natl Acad Sci USA 99(10), 6943-
6948. 
95. Yamada S, Yamaguchi T, Hosoda A, Iwawaki T, Kohno K (2006) Regulation of human 
STARD4 gene expression under endoplasmic reticulum stress. Biochem Biophys Res 
Commun 343(4), 1079-1085. 
21 
 
96. Hanada, K., Kuamagai, K., Miura, Y., Kawano, M., Fukasaura, M., Nishijima, M. (2003) 
Molecular machinery for non-vesicular trafficking of ceramide. Nature 426(6968), 803-9. 
97. Horibata, Y., Sugimoto, H. (2010) StarD7 mediates the intracellular trafficking of 
phosphatidylcholine to mitochondria. J Biol Chem 285(10), 7358-65. 
98. Olayioye, M.A., Vehring, S., Muller, P., Herrmann, A., Schiller, J., Thiele, C., Lindeman, G.J., 
Visvader, J.E., Pomorski, T. (2005) StarD10, a START domain protein overexpressed in 
breast cancer, functions as a phospholipid transfer protein. J Biol Chem 280(29),27436-42. 
99. Kang, HW, Kanno K, Scapa EF, Cohen DE (2010) Regulatory role for phosphatidylcholine 
transfer protein/StarD2 in the metabolic response to peroxisome proliferator activated 
receptor alpha (PPARalpha). Biochim Biophys Acta 1801(4), 496-502. 
100. Torres JZ, Summers MK, Peterson D, Brauer MJ, Lee J, Senese S, Gholkar AA, Lo 
YC, Lei X, Jung K, Anderson DC, Davis DP, Belmont L, Jackson PK (2011) The 
STARD9/Kif16a kinesin associates with mitotic microtubules and regulates spindle pole 
assembly. Cell 147(6), 1309-23. 
101. Miki H, Okada Y, Hirokawa N (2005) Analysis of the kinesin superfamily: insights 
into structure and function. Trends Cell Biol 15(9), 467-76. 
102. Braun AC, Hendrick J, Eisler SA, Schmid S, Hausser A, Olayioye MA (2015) The Rho-
specific GAP protein DLC3 coordinates endocytic membrane trafficking. J Cell Sci 
128(7),1386-99. 
103. Kirkby B, Roman N, Kobe B, Kellie S, Forwood JK. (2010) Functional and structural 
properties of mammalian acyl-coenzyme A thioesterases. Prog Lipid Res 49(4), 366-77. 
104. Suematsu N, Isohashi F (2006) Molecular cloning and functional expression of 
human cytosolic acetyl-CoA hydrolase. Acta Biochim Pol 53(3), 553-61. 
105. Adams SH, Chui C, Schilbach SL, Yu XX, Goddard AD, Grimaldi JC, Lee J, Dowd 
P, Colman S, Lewin DA.(2001) BFIT, a unique acyl-CoA thioesterase induced in thermogenic 
brown adipose tissue: cloning, organization of the human gene and assessment of a 
potential link to obesity. Biochem J 360(Pt 1), 135-42. 
106. Olkkonen VM (2015) OSBP-related protein family in lipid transport over membrane 
contact sites.  Lipid Insights 8(Suppl 1), 1-9. 
107. Taylor FR, Saucier SE, Shown EP, Parish EJ, Kandutsch A (1984) Correlation 
between oxysterol binding to a cytosolic binding protein and potency in the repression of 
hydroxymethylglutaryl coenzyme A reductase. J Biol Chem 259(20), 12382-7. 
108. Miller WL, Bose HS (2011) Early steps in steroidogenesis: intracellular cholesterol 
trafficking.  J Lipid Res 52(12), 2111-2135. 
109. Manna PR, Dyson MT, Stocco DM (2009) Regulation of the steroidogenic acute 
regulatory protein gene expression: present and future perspectives.  Mol Hum Reprod 
6:321-333. 
110. Miller WL (2016) Disorders in the initial steps of steroid hormone synthesis. J 
Steroid Biochem Mol Biol. Pii:S0960-0760(16)330055-3, doi:10.1016/j.jsbmb.2016.03.009. 
[Epub ahead of print] 
111. Manna PR, Stetson CL, Slominski AT, Pruitt K (2016) Role of the steroidogenic acute 
regulatory protein in health and disease.  Endocrine 51(1):7-21. 
112. Miller WL (2007) Steroidogenic acute regulatory protein (StAR), a novel 
mitochondrial cholesterol transporter.  Biochim Biophys Acta 1771(6):663-676. 
113. King SR, Bhangoo A, Stocco DM (2011) Functional and physiological consequences of StAR 
deficiency: rold in lipoid congential adrenal hyperplasia.  Endocr Dev 29: 47-53. 
114. Hasegawa T, Zhao L, Caron KM, Majdic G, Suzuki T, Shizawa S, Sasano H, Parker 
KL (2000) Developmental roles of the steroidogenic acute regulatory protein (StAR) as 
revealed by StAR knockout mice.  Mol Endocrinol. 14:1462-1471. 




116. Fujieda K, Okuhara K, Abe S, Tajima T, Mukai T, Nakae J (2003) Molecular 
pathogenesis of lipoid adrenal hperplasia and adrenal hypoplasia congenita.  J Steroid 
Biochem Mol Biol 85(2-5), 483-489. 
117. Stocco DM (2002) Clinical disorders associated with abnormal cholesterol transport: 
mutations in the steroidogenic acute regulatory protein.  Mol Cell Endocrinol 191(1), 19-25. 
118. Jehaimi CT, Araiza VC, Batish SD, Brosnan PG (2010) Polycystic ovaries and adrenal 
insufficiency in a young pubescent female with lipoid congenital adrenal hyperplasia due to 
a splice mutation of the StAR gene: a case report and review of the literature.  J Pediatr 
Endocrinol Metab 23(12), 1225-1231. 
119. Anuka G, Gal M, Stocco DM, Orly J (2013) Expression and roles of steroidogenic 
acute regulatory (StAR) protein in ‘non-classical’, extra-adrenal and extra-gonadal cells and 
tissues. Mol Cell Endocrinol 371:47-61. 
120. Ning, Y., Chen, S., Li, X., Ma, Y., Zhao, F and Yin, L. (2006) Cholesterol, LDL and 25-
hydroxycholesterol regulate expression of the steroidogenic acute regulatory protein in 
microvascular endothelial cell line (bEnd.3).  Biochem.Biophys. Res. Commun. 342: 1249-
1256. 
121. Ma Y, Ren S, Pandak WM, Li X, Ning Y, Lu C, Zhao F, Yin L (2007) The effects of 
inflammatory cytokines on steroidogenic acute regulatory protein expression in 
macrophages.  Inflamm Res 56:495-501. 
122. Borthwick F, Taylor JM, Bartholomew C, Graham A (2009) Differential regulation of 
the STARD1 subfamily of START lipid trafficking proteins in human (THP-1) macrophages.  
FEBS Lett 583:1147-1153. 
123. Taylor JMW, Borthwick F, Bartholomew C, Graham A (2010) Overexpression of 
steroidogenic acute regulatory protein increases macrophage cholesterol efflux to 
apolipoprotein A-I.  Cardiovasc Res 86:526-534. 
124. Graham A, Borthwick F, Taylor J (2014).  Steroidogenic acute regulatory protein 
(StAR) and atherosclerosis.  In ‘Cholesterol transporters of the START domain protein 
family in health and disease’ Eds. Barbara Clark and Doug Stocco.   New York: Springer 
Science, 99-117. 
125. Kortowski W, Wawak K, Pabisz P, Schmitt JC, Girotti AW (2015) Macrophage 
mitochondrial damage from StAR transport of 7-hydroperoxycholesterol: implications for 
oxidative stress-impaired reverse cholesterol transport.  FEBS Lett 588:65-70. 
126. Ning T, Xu L, Ren S, Pandak WM, Chen S, Yin L (2009) StAR overexpression 
decreases serum and tissue lipids in apolipoprotein E-deficient mice.  Lipids 44:511-519. 
127. Ren S, Hylemon P, Marques D, Hall E, Redford K, Gil G, Pandak WM (2004) Effect of 
increasing the expression of cholesterol transporters (StAR, MLN64, SCP-2) on bile acid 
synthesis.  J Lipid Res 45:2123-31. 
128. Soffientini, U, Caridis, A-M, Dolan, S , Graham A (2014) Intracellular cholesterol 
transporters and modulation of hepatic lipid metabolism: implications for diabetic 
dyslipidaemia and steatosis.  Biochim Biophys Acta 1841:1372-1382. 
129. Galmes R, Houcine A, van Vliet ARM Agonstinis P, Jackson CL, Giordano F (2016) 
ORP5/ORP8 localise to endoplasmic reticulum-mitochondria contacts and are involved in 
mitochondrial function.  doi:10.15252/embro.201541108. 
130. Soccio RE, Adams R, Maxwell KN, Breslow JL (2005) Differential gene regulation of 
StarD4 and StarD5 cholesterol transfer proteins.  Activation of StarD4 by sterol regulatory 
element-binding protein-2 and StarD5 by endoplasmic reticulum stress.  J Biol Chem. 
280(9):19410-19418. 
131. Letourneau D, Lefebvre A, Lavigne P, LeHous JG (2015) The binding site specificity of 
STARD4 subfamily: breaking the cholesterol paradigm.  Mol Cell Endocrinol 408:53-61. 
23 
 
132. Rodriguez-Agudo D, Ren S, Wong E, Marques D, Redford K, Gil G, Hylemon P, 
Pandak WM (2009) Intracellular cholesterol transporter StarD4 binds free cholesterol and 
increases cholesteryl ester formation.  J Lipid Res 49(7): 1409-1419. 
133. Soffientini U, Dolan S, Graham A (2015) Cytosolic lipid trafficking proteins STARD4 and 
STARD5 regulate hepatic neutral lipid metabolism: implications for diabetic dyslipidaemia 
and steatosis.  J Diabetes Metab 6:6  
134. Iaea DB, Dikiy I, Kiburu I, Eliezer D, Maxfield KR (2015) STARD4 membrane 
interactions and sterol binding.  Biochemistry 54(3):4623-4636. 
135. Rodriguez-Agudo D, Ren S, Wong E, Marques D, Redford K, Gil G, Hylemon P, 
Pandak WM (2008)  Intracellular cholesterol transporter StarD4 binds free cholesterol and 
increase cholesteryl ester formation.  J Lipid Res 49:1409-1419. 
136. Rodriguez-Agudo D, Calderon-Dominguez M, Ren S, Marques D, Redford K, 
Medina-Torres MA, Hylemon P, Gil G, Pandak WM (2011) Subcellular localisation and 
regulation of StarD4 protein in macrophages and fibroblasts.  Biochim Biophys Acta 
1281:597-606. 
137. Garbarino J, Pan M, Chin HF, Lund FW, Maxfield FT, Breslow JL (2012) STARD4 knockdown 
in HepG2 cells disrupts cholesterol trafficking associated with the plasma membrane, ER 
and ERC.  J Lipid Res 53:2716-2725. 
138. Elbadawy HM, Borthwick F, Wright C, Martin PE, Graham A (2011) Cytosolic StAR-
related lipid transfer domain 4 (STARD4) protein influences keratinocyte lipid phenotype 
and differentiation status.  Br J Dermatol 164(3):628-632. 
139. Bazuine M, Stenkula KG, Cam M, Arroyo M, Cushman SW (2009) Guardian of 
corpulence: a hypothesis on p53 signaling in the fat cell. Clin Lipidol 4(2):231-243. 
140. Korytowski W, Rodriguez-Agudo D, Pilat A, Girotti AW (2010) StarD4-mediated 
translocation of 7-hydroperoxycholesterol to isolated mitochondria: deleterious effects and 
implications for steroidogenesis under oxidative stress conditions. Biochem Biophys Res 
Commun 293(1):58-62. 
141. Riegelhaupt JJ, Waase MP, Garbarino J, Cruz DE, Breslow JL (2010) Targeted 
disruption of steroidogenic acute regulatory protein D4 leads to modest weight reduction 
and minor alterations in lipid metabolism.  J Lipid Res. 51:1134-1143. 
142. Rodriguez-Agudo D, Ren S, Hylemon PB, Redford K, Natarajan R, Del Castillo A, Gil 
G, Pandak WM (2005).  Human StarD5, a cytosolic StAR-related lipid binding protein.  J 
Lipid Res 46(8)1615-1623. 
143. Rodriguez-Agudo D, Ren S, Hylemon PB, Montanez R, Redford K, Natarajan R, 
Medina MA, Gil G, Pandak WM (2006) Localization of StarD5 cholesterol binding proteinJ 
Lipid Res 47(6)1168-1175. 
144. LeTourneau D, Lefebvre A, Lavigne P, LeHoux JG (2013) STARD5 specific ligand 
binding : comparison with STARD1 and STARD4 subfamilies. Mol Cell Endocrinol 371(1-
2):20-25. 
145. LeTourneau D, Lorin A, Lefebvre A, Frappier V, Gaudreault F, Najmanovich R, 
Lavigne P, LeHous JG (2012) StAR-related lipid transfer domain protein 5 binds primary bile 
acids.  J Lipid Res 53:2677-2689. 
146. LeTourneau D, Lorin A, Lefebvre A, Cabana J, Lavigne P, Le Houx JG (2013) 
Thermodynamic and solution state NMR characterisation of the binding of secondary and 
conjugated bile acids to STARD5.  Biochim Biophys Acta 1831:1588-99 
147. Rodriguez-Agudo D, Calderon-Dominguez M, Medina MA, Ren S, Gil G, Pandak 
WM (2012) ER stress increases StarD5 expression by stabilising its mRNA and leads to 
relocalisation of its protein from the nucleus to the membranes.  J Lipid Res 53(12):2708-
2715. 
148. Isihikawa T, Hwang K, Lazzarino D, Morris PL (2005) Sertoli cell expression of 
steroidogenic acute regulatory protein-related lipid transfer 1 and 5 domain-containing 
24 
 
proteins and sterol regulatory element binding protein-1 are interleukin-1 beta regulated by 
activation of c-Jun N-terminal kinase and cyclooxygenase-2 and cytokine induction.  
Endocrinology 46(12):5100-5111. 
149. Bose HS, Whittal RM, Ran Y, Bose M, Baker BY, Miller WL (2008) StAR-like activity 
and molten globule behaviour of StARD6, a male germ-line protein.  Biochemistry 
47(8):2277-88. 
150. LaVoie HA, Whitfield NE, Shi B, King SR, Bose HS, Hui YY (2014) STARD6 is 
expressed in steroidogenic cells of the ovary and can enhance de novo steroidogenesis.  Exp 
Biol Med 239(4):430-435. 
151. Chang IY, Ohn T, Jeon YJ, Lee KH, Kim JW, Kim IY, Yoon SP (2014) A comparison of 
the steroidogenic acute regulatory protein-related lipid transfer (START) domain-
containing 6 on the brain and testes between young and aged rats.  Acta Histochem 
116(4):551-558.   
152. Chang IY, Ohn T, Ko GS, Yoon Y, Kim JW, Yoon SP (2012) Immunolocalisation of 
steroidogenic acute regulatory protein-related lipid transfer (START) domain-containing 
proteins in the developing cerebellum of normal and hypothyroid rats.  J Chem Neuroanat 
43(1):28-33. 
153. Chang IY, Kim JH, Hwang G, Song PI, Song RJ, Kim JW, Yoon SP (2007) 
Immunohistochemical detection of StarD6 in the rat nervous system.  Neuroreport 
18(15):1615-1619. 
154. Johansson M,  Bocher V, Lehto M, Chinetti G, Kuismanen E, Ehnholm C, Staels B, 
Olkkonen VM (2003) The two variants of oxysterol binding protein-related protein-1 display 
different tissue expression patterns, have different intracellular localisation, and are 
functionally distinct.  Mol Biol Cell 14(3):903-915. 
155. Lee S, Wang PY, Jeong Y, Mangelsdorf DJ, Anderson RG, Michaely P (2012) Sterol-
dependent nuclear import of ORP1S promotes LXR regulated trans-activation of apoE.  Exp 
Cell Res 318(6):2128-2142. 
156. Jansen M, Ohsaki Y, Rega LR, Bittman R, Olkkonen VM, Ikonen E (2011) Role of 
ORPs in sterol transport from plasma membrane to ER and lipid droplets in mammalian 
cells.  Traffic 12(2):218-231. 
157. Vihervaara T, Jansen M, Uronen RL, Ohsaki Y, Ikonen E, Olkkonen VM (2011) Cytoplasmic 
oxysterol-binding proteins: sterol sensors or transporters?  Chem Phys Lipids 164(6):443-
450. 
158. Goto A, Charman M, Ridgway ND (2016) Oxysterol-binding protein activation at 
endoplasmic reticulum-Golgi contact sites reorganises phosphatidylinositol 4-phosphate 
pools.  J Biol Chem 291(3):1336-1347. 
159. Peretti D, Dahan N, Shimoni E, Hirschberg K, Lev S (2008) Coordinated lipid 
transfer between the endoplasmic reticulum and the Golgi complex requires the VAP 
proteins and is essential for Golgi-mediated transport.  Mol Biol Cell 19(9):3871-84. 
160. Nishimura T, Uchida Y, Yachi R, Kudlyk T, Lupashin V, Inoue T, Taguchi T, Arai H 
(2013) Oxysterol-binding protein (OSBP) is required for the perinuclear localisation of intra-
Golgi v-SNAREs.  Mol Biol Cell 24(33): 3534-3544. 
161. Mesmin B, Bigay J, Moser von Filseck J, Lacas-Gervais S, Drin G, Antonny B (2013) A 
four-step cycle driven by PI(4)P hydrolysis directs sterol/PI(4)P exchange by the ER-Golgi 
tether OSBP.  Cell 155(4):830-843. 
162. Wang H, Perry JW, Lauring AS, Neddermann P, De Francesco R, Tai AW (2014) 
Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HC V 




163. Yan D, Lehto M, Rasilainen L, Metso J, Ehnholm C, Yla-Herttuala S, Jauhiainen M, 
Olkkonen VM (2007) Oxysterol binding protein induces upregulation of SREBP-1c and 
enhances hepatic lipogenesis.  Arterioscler Thromb Vasc Biol 27(5):1108-1114. 
164. Bowden K, Ridgway ND (2008) OSBP negatively regulates ABCA1 protein stability.  
J Biol  Chem 283(26):18210-7. 
165. Ma Z, Liu Z, Huang X (2010) OSBP- and FAN-mediated sterol requirement for 
spermatogenesis in Drosophila. Development 173(22):3775-3784. 
166. Zhong W, Zhou Y, Li S, Zhou T, Ma H, Wei K, Li H, Olkkonen VM, Yan D (2011) 
OSBP-related protein 7 interacts with GATE-16 and negatively regulates GS28 protein 
stability.  Exp Cell Res 317(6):2353-2363. 
167. Ngo M, Ridgway ND (2009) Oxysterol binding protein-related protein 9 (ORP9) is a 
cholesterol transfer protein that regulates Golgi structure and function.  Mol Cell Biol 
20(5):1388-1399. 
168. Wyles JP, Ridgway ND (2004) VAMP-associated protein-A regulates partitioning of 
oxysterol binding protein-related protein-9 between the endoplasmic reticulum and Golgi 
apparatus.  Exp Cell Res 297(2):533-547. 
169. Liu X, Ridgway ND (2014) Characterisation of the sterol and phosphatidylinositol 4-
phosphate binding properties of Golgi-associated OSBP-related protein (ORP9).  PLoS One 
9(9):e108368. 
170. Chung J, Torta F, Masai K, Lucast L, Czapla H, Tanner LB, Narayanasawmy P, Wenk 
MR, Nakatsu F, De Camilli P (2015) Intracellular transport.  PI4P/phosphatidylserine 
countertransport at ORP5- and ORP8-mediated ER-plasma membrane contacts.  Science 
349(6246):428-432. 
171. Du X, Kumar J, Ferguson C, Schulz TA, Ong YS, Hong W, Prinz WA, Parton RG, Brown AJ, 
Yang H (2011) A role for oxysterol-binding protein-related protein 5 in endosomal 
cholesterol trafficking.  J Cell Biol 192(1): 121-135. 
172. Ishikawa S, Nagai Y, Masuda T, Koga Y, Nakamura T, Imamura Y, Takamori H, 
Hirota M, Funakosi A, Fukushima M, Baba H (2010) The role of oxysterol binding protein-
related protein 5 in pancreatic cancer.  Cancer Sci 101(4):898-905. 
173. Koga Y, Ishikawa S, Nakamura T, Masuda T, Nagai Y, Takamori H, Hirota M, Kanemitsu K, 
Baba Y, Baba H (2008) Oxysterol binding protein-related protein-5 is related to invasion and 
poor prognosis in pancreatic cancer.  Cancer Sci 99(10):2398-2394. 
174. Spadi R, Brusa F, Ponzetti A, Chiappino I, Birocco N, Ciuffreda L, Satolli MA (2016) 
Current therapeutic strategies for advanced pancreatic cancer: a review for clinicians.  
World J Clin Oncol 7(1), 27-43. 
175. Tsutsumi Y, Tsunoda S (2015) Identification and evaluation of metastasis-related proteins, 
oxysterol binding protein-like 5 and calumenin, in lung tumours.  Int J Oncol 47(1), 195-203. 
176. Zhou T, Li S, Zhong W, Vihervaara T, Beaslas O, Perttila J, Luo W, Jiang Y, Lehto M, 
Olkkonen VM, Yan D (2011) OSBP-related protein 8 (ORP8) regulates plasma and liver 
tissue lipid levels and interacts with the nucleoporin Nup62.  PLoS One 6(6), e21078 
177. Zhong W, Zhou Y, Li J, Mysore R, Luo W, Li S, Chang MS, Olkkonen VM, Yan D (2014) 
OSBP-related protein 8 (ORP8) interacts with Homo sapiens sperm associated antigen 5 
(SPAG5) and mediates oxysterol interference of HepG2 cell cycle.  Exp Cell Res 322(2),  227-
235. 
178. Beaslas O, Vihervaara T, Li J, Laurila PP, Yan D, Olkkonen VM (2012) Silencing of 
OSBP-related protein 8 (ORP8) modifies the macrophage transcriptome, nucleoporin p62 
distribution, and migration capacity.  Exp Cell Res 318(15), 1933-1945. 
179. Yan D, Mayranpaa MI, Wong J, Perttila J, Lehto M, Jauhiainen M, Kovanen PT, 
Ehnholm C, Brown AJ, Olkkonen VM (2008) OSBP-related protein 8 (ORP8) suppresses 
ABCA1 expression and cholesterol efflux from macrophages.  J Biol Chem 283(1), 332-340. 
26 
 
180. Beaslas O, Metso J, Nissila E, Laurila PP, Kaiharju E, Batchu KC, Kaipianen L, 
Mayranpaa MI, Yan D, Gylling H, Jauhiainen M, Olkkonen VM (2013) Osbpl8 deficiency in 
mouse causes an elevation of high-density lipoproteins and gender-specific alterations of 
lipid metabolism.  PLoS One 8(3), e58856. 
181. Van Kempen E, Beaslas O, Hildebrand RB, Lammers B, Van Berkel TJ, Olkkonen 
VM, Van Eck M (2014) Orp8 deficiency in bone-marrow derived cells reduces atherosclerotic 
lesion progression in LDL receptor knockout mice.  PLoS One 9(10), e109024 
182. Jordan SD, Kruger M, Willmes DM, Redemann N, Wunderlich FT, Bronneke HS, 
Merkwith C, Kashkar H, Olkkonen VM, Bottger T, Braun T, Seibler J, Bruning JC (2011) 
Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation 
and impairs glucose metabolism.  Nat Cell Biol 13(4), 434-446. 
183. Pfisterer SG, Peranan J, Ikonen E (2016) LDL-cholesterol transport to the 
endoplasmic reticulum: current concepts.  Curr Opin Lipidol Apr 14 [Epub ahead of print]. 
184. Du X and Yang H (2013) Endosomal cholesterol trafficking: protein factors at a 
glance.  Acta Biochim Biophys  Sin (Shanghai) 45(1), 11-17. 
185. Cianciola NL, Greene NJ, Morton RE, Carlin CR (2013) Adenovirus RID uncovers a 
novel pathway requiring ORP1L for lipid droplet formation independent of NPC1.  Mol Biol 
Cell 24(21), 3309-3325. 
186. van der Kant R, Fish A, Janssen L, Janssen H, Krom S, Ho N, Brummelkamp T, 
Carette J, Rocha N, Neefjes J (2013) Late endosomal transport and tethering are coupled 
processes controlled by RILP and the cholesterol sensor ORP1L.  J Cell Sci 126(15), 3462-
3474. 
187. van der Kant R, Zondervan I, Janssen L, Neefjes J (2013) Cholesterol binding 
molecules MLN64 and ORP1L mark distinct late endosomes with transporters ABCA3 and 
NPC1.  J Lipid Res 54(8), 2153-2165. 
188. Moog-Lutz, Tomsetto C, Regnier CH, Wendling C, Lutz Y, Muller D, Chenard MP, 
Basset P, Rio MC (1997) MLN64 exhibits homology with the steroidogenic acute regulatory 
protein (StAR) and is over-expressed in human breast carcinomas.  Int J Cancer 71(2), 183-
191. 
189. Wilhelm LP, Tomasetto C, Alpy F (2016) Touche! STARD3 and STARD3NL tether 
the ER to endosomes.  Biochem Soc Trans 44(2), 493-498. 
190. Alpy F, Rousseau A, Schwab Y, Legueux F, Stoll I, Wendling C, Spiegelhalter C, 
Kessler P, Mathelin C, Rio MC, Levine TP, Tomasetto C (2013) STARD3 or STARD3NL and 
VAP form a novel molecular tether between late endosomes and the ER.  J Cell Sci 126(23), 
5500-12. 
191. Watari H, Arakane F, Moog-Lutz C, Kallen CB, Tomasetto C, Gerton GL, Rio MC, 
Baker ME, Strauss JF 3rd. (1997) MLN64 contains a domain with homology to the 
steroidogenic acute regulatory protein (StAR) that stimulates steroidogenesis.  Proc Natl 
Acad Sci USA 94(16), 8462-7 
192. Borthwick F, Allen AM, Taylor JM, Graham A (2010) Overexpression of StarD3 in 
human monocyte/macrophages induces an anti-atherogenic lipid phenotype.  Clin Sci 
(Lond) 119(7), 265-272. 
193. Kishida T, Kostetskii I, Zhang Z, Martinez F, Liu P, Walkley SU, Dwyer NK, 
Blanchette-Mackie EJ, Radice GL, Strauss JF 3rd (2004) Targeted mutation of the MLN64 
START domain causes only modest alterations in cellular sterol metabolism. J Biol Chem 
279, 19276-85. 
194. Stigliano A, Gandini O, Cerquetti L, Gazzaniga P, Misiti S, Monti S, Gradilone A, 
Falasca P, Poggi M, Brunetti E, Agliano AM, Toscano V (2007) Increased metastatic lymph 




195. Cai W, Ye L, Sun J, Mansel RE, Jiang WG (2010) Expression of MLN64 influences 
cellular matrix adhesion of breast cancer cells, the role for focal adhesion kinase.  Int J Mol 
Med 25(4), 573-580. 
196. Ouimet M, Hennessy EJ, van Solingen C, Koelwyn GJ, Hussein MA, Ramkhelawon B, 
Rayner KJ, Temel RE, Perisic L, Hedin U, Maegdefessel L, Garabedian MJ, Holdt LM, 
Heupser D, Moore KJ (2016) miRNA targeting of oxysterol-binding protein-like 6 regulates 
cholesterol trafficking and efflux.  Arterioscler Thromb Vasc Biol pii:ATVBAHA.116.307282 
[Epub ahead of print]. 
197. Hynynen R, Suchanek M, Spandl J, Back N, Thiele C, Olkkonen VM (2009) OSBP-
related protein 2 is a sterol receptor on lipid droplets that regulates the metabolism of 
neutral lipids.  J Lipid Res 50(7), 1305-1315. 
198. Escajadillo T, Wang H, Li L, Li D, Sewer MB (2016) Oxysterol-related-binding-
protein related protein-2 (ORP2) regulates cortisol biosynthesis and cholesterol 
homeostasis.  Mol Cell Endocriniol 427, 73-85. 
199. Thoenes M, Zimmermann U, Ebermann I, Ptok M, Lewis MA, Thiele H, Morlot S, 
Hess MM, Eisenberger T, Bergmann C, Nurnberg G, Nurnberg P, Steel KP, Knipper M, Bolz 
HJ (2015) OSBPL2 encodes a protein of inner and outer hair cell stereocilia and is mutated in 
autosomal dominant hearing loss (DFNA67).  Orphanet J Rare Dis 10, 15. 
200. Xing G, Yao J, Wu B et al (2013) Identification of OSBP2 as a novel candidate gene 
for progressive nonsyndromic hearing loss by whole exome-sequencing.  Genet Med 
17(3)210, 218. 
201. Egilmez OK, Talcioglu MT (2016) Genetics of nonsyndromic congenital hearing loss.  
Scientifica 2016, ID7576064; http://dx,doi.org/10.1155/2016/7576064. 
202. Malgrange B, Varela-Nieto I, de Medina P, Paillasse MR (2015) Targeting cholesterol 
homeostasis to fight hearing loss: a new perspective.  Front Aging Neurosci 7,3. 
203. Wang C, JeBailey L, Ridgway ND (2002) Oxysterol-binding protein (OSBP)-related 
protein 4 binds 25-hydroxycholesterol and interacts with vimentin intermediate filaments.  
Biochem J 361(3), 461-472. 
204. Park IW, Ndjomou J, Wen Y, Liu Z, Ridgway ND, Kao CC, He JJ (2013) Inhibition of 
HCV replication by oxysterol-binding protein-related protein 4 (ORP4) through interaction 
with HCV NS5B and alteration of lipid droplet formation.  PLoS One 8(9), e75648. 
205. Murakami M, Ogura A, Inoue T, Toshimori K, Arai H (2014) Oligo-astheno-
teratozoospermia in mice lacking ORP4, a sterol-binding protein in the OSBP-related 
protein family.  Genes Cells 19(1), 13-27. 
206. Nissila E, Ohsaki Y, Weber-Boyvat M, Perttila J, Ikonen E, Olkkonen VM (2012) 
ORP10, a cholesterol binding protein associated with microtubules regulates apolipoprotein 
B-100 secretion.  Biochim Biophys Acta 1821(12), 1472-1484. 
207. Ma Z, Liu Z, Huang X (2010) OSBP- and FAN-mediated sterol requirement for 
spermatogenesis in Drosophila.  Development 137, 3775-3784. 
208. Koriyama H, Nakagami H, Katsuya T, Akasaka H, Saitoh S, Shimamoto K, Ogihara 
T, Kaneda Y, Morishita R, Rakugi H (2010) Variation in OSBP10 is associated with 
dyslipidaemia.  Hypertens Res 33(5), 511-514. 
209. Koriyama H, Nakagami H, Katsuya T, Sugimoto K, Yamashita H, Takami Y, Maeda 
S, Kubo M, Takahashi A, Nakamura Y, Ogihara T, Rakugi H, Kaneda Y, Morishita R (2010) 
Identification of evidence suggestive of an association with peripheral arterial disease at the 
OBSP10 locus by genome-wide investigation in the Japanese population.  J Atheroscler 
Thromb 17(10), 1054-62. 
210. Chitrala KN, Yeguvapalli S (2014) Ligand based virtual screening to predict 
inhibitors against metastatic lymph node 64.  J Recept Signal Transduct Res 34(2), 92-96. 
211. Li B, Vachali P, Frederick JM, Bernstein PS (2011) Identification of StARD3 as a 
lutein-binding protein in the macular of the primate retina.  Biochemistry 50(13), 2541-9. 
28 
 
212. Nagano K, Imai S, Zhao X, Yamashita T, Yoshioka Y, Abe Y, Mukai Y, Kamada H, 
Nakagawa S, Albulescu L, Strating JR, Thibaut HJ, van der Linden L, Shair MD, Neyts J, Van 
Kuppeveld FJ (2015) Broad-range inhibition of enterovirus replication by OSW-1, a natural 
compound targeting OSBP.  Antiviral Res 117, 110-114. 
213. Bao X, Zheng W, HataSugi N, Agarwala KL, Xu Q, Wang Z, Tendyke K, Lee W, 
Parent L, Li W, Cheng H, Shen Y, Taylor N, Dezso Z, Du H, Kotake Y, Zhao N, Wang J, 
Postema M, Woodall-Jappe M, Takase Y, Uenaka T, Kingston DG, Nomoto K (2015) Small 
molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT 
signalling by interfering with trans-Golgi-network trafficking.  Cancer Biol Ther 16(4), 589-
601. 
214. Strating JR, van der Linde L, Albulescu L, Bigay J, Arita M, Delang L, Leyssen P, van 
der Schaar HM, Lanke KH, Thibaut HJ, Ulferts R, Drin G, Schlinck N, Wubbolts RW, Sever N, 
Head SA, Liu JO, Beachy PA, De Matteis MA, Shair MD, Olkkonen VM, Neyts J, van 
Kuppveld FJ (2015) Itraconazole inhibits enterovirus replication by targeting the oxysterol-
binding protein.  Cell Rep 10(4), 600-615. 
215. Burgett AW, Poulsen TB, Wangkanont K, Anderson DR, Kikuchi C, Shimada K, 
Okubo S, Fortner KC, Mimaki Y, Kuroda M, Murphy JP,Schwalb DJ, Petrella EC, Cornella-
Taracido I, Schirle M, Tallarico JA, Shair MD (2011) Natural products reveal cancer cell 
dependence on oxysterol-binding proteins.  Nat Chem Biol 7(9), 639-647. 




Legend to Figure 1 Intracellular sterol transport via membrane contact sites (MCS) and non-
vesicular trafficking 
A) Lipoprotein-derived cholesterol is delivered to the endocytic pathway, via lipoprotein 
receptors internalised by clathrin-coated pits, to early endosomes (EE) where the lower pH 
separates the lipoprotein from its receptor, which is recycled back to the plasma membrane 
via the endocytic recycling compartment (ERC).  The lipoprotein remains within the EE as 
they mature to late endosomes (LE)/lysosomes wherein it is hydrolysed to free cholesterol, 
fatty acids, and amino acids.  Niemann Pick C-1/2 proteins aid transport of cholesterol out 
of the LE/lysosomes for transport to the plasma membrane (PM) and endoplasmic 
reticulum (ER).  Cholesterol transported to the endoplasmic reticulum (ER) sequesters 
Sterol Regulatory Element Binding Protein (SREBP)/SREBP-cleavage activating protein 
complex at this site; oxysterols (below) enhance this process by binding to Insig-1/2 (insulin-
induced gene-1 or -2), thereby achieving repression of endogenous cholesterol 
biosynthesis.  Excess cholesterol is esterified via ACAT-1/2, storing cholesteryl ester as lipid 
droplets within the cytoplasm as ‘foamy’ deposits.  Delivery of cholesterol to mitochondria 
can increase the endogenous production of oxysterol ligands by sterol 27-hydroxylaase 
(CYP27A1) for Liver X Receptors (LXR .  Ligation of the LXR/Retinoid X Receptor (RXR) 
heterodimer allows the recruitment of coactivator proteins, increasing the transcription of 
ATP binding cassette (ABC) transporters, ABCA1, ABCG1 and ABCG4, which efflux 
cholesterol to apolipoprotein (apo) A-I, apoE or nascent high density lipoprotein (HDL).  EE= 
early endosome; ER= endoplasmic reticulum; ERC= endocytic recycling compartment; LD= 
lipid droplets; LE= late endosome; PM= plasma membrane; CG= cis-Golgi; TG= trans-Golgi.   
B) Intracellular trafficking of cholesterol can be achieved by vesicular (blue arrows) and non-
vesicular (red dotted arrows) transport, and by exchange over membrane contact sites 
(green arrows).   The distribution of cholesterol differs significantly between organelles, 
with the PM, ERC and EE being highly enriched with cholesterol compared with the ER, 
mitochondria and lysosomes, which are relatively cholesterol-poor; the Golgi 
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cholesterol:phospholipid ratio is intermediate between that of PM and the ER, with the 
cholesterol content increasing from the cis (CG) to the trans-Golgi (TG) network [207].   
Cholesterol transfer between organelles does occur by vesicular trafficking, particularly 
within the endocytic and secretory pathways, but the majority appears to occur via non-
vesicular, carrier-mediated transport [215].   
The key members of the ORP and START families of lipid-trafficking/exchange proteins 
implicated in exchange of lipids across MCS, and in trafficking sterol between organelles.  
Mitochondrial cholesterol transport from the outer to the inner mitochondrial membrane 
can be facilitated by StAR, STARD3 and STARD6, while the presence of ORP5 and ORP8 at 
ER-mitochondrial membrane contact sites influences mitochondrial morphology and 
respiration; ORP5 and ORP8 can also tether the ER to the PM, aid endosomal trafficking 
and modulate cholesterol and lipoprotein metabolism.    Cytosolic STARD4 modulates 
cholesterol trafficking between the ERC, ER, mitochondria and the PM, while ORP1S and 
ORP2 can stimulate sterol transport from PM to LD.  STARD5 is involved in the ER stress 
response, can modulate the free cholesterol content of intracellular membranes and  
increase the basal synthesis of triacylglycerol.   At ER-Golgi membrane contact sites OSBP, 
ORP9 and ORP11 are involved with sterol/PI-4P exchange, influencing the localisation of 
vSNAREs, cell growth, cholesterol and triacylglycerol metabolism.  Within the endocytic 
pathway, ORP1L interacts with NPC-2 to deliver cholesterol to LD, and sustain serum levels 
of HDL; STARD3 and ORP6 facilitate endosomal cholesterol trafficking to mitochondria, ER 
and/or the PM, regulating cholesterol efflux and HDL levels.  Finally, ORP2 and ORP4 are 
found at ER-LD membrane contact sites, influencing cholesterol metabolism and 
cytoskeletal function, ORP10 influences the packaging and secretion of VLDL, and evidence 
exists for nuclear localisation of ORP1S, ORP8 and ORP2.   
Figure 1C The links between dysregulated expression (↑ or ↓) or mutations in 
members of the ORP and START lipid trafficking families of proteins, and disease 
conditions, including atherosclerosis, dyslipidaemia, diabetes, congenital lipoid hyperplasia, 
cancer, autosomal dominant hearing loss and male infertility.  The images used here were 
adapted from Iaea and Maxfield (2015) [215].    
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